OX40	O
stimulation	O
by	O
gp34/OX40	B-protein
ligand	I-protein
enhances	O
productive	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
.	O

OX40	B-protein
is	O
a	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
receptor	I-protein
superfamily	I-protein
and	O
known	O
to	O
be	O
an	O
important	O
costimulatory	B-protein
molecule	I-protein
expressed	O
on	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

To	O
investigate	O
the	O
role	O
of	O
costimulation	O
of	O
OX40	B-protein
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
by	O
its	O
natural	O
ligand	O
,	O
gp34	B-protein
,	O
the	O
OX40-transfected	B-cell_line
ACH-2	I-cell_line
cell	I-cell_line
line	I-cell_line
,	I-cell_line
ACH-2/OX40	I-cell_line
,	O
chronically	O
infected	O
with	O
HIV-1	O
,	O
was	O
cocultured	O
with	O
paraformaldehyde	O
(	O
PFA	O
)	O
-fixed	O
gp34-transfected	B-cell_line
mouse	I-cell_line
cell	I-cell_line
line	I-cell_line
,	I-cell_line
SV-T2/gp34	I-cell_line
.	O

The	O
results	O
showed	O
that	O
HIV-1	O
production	O
was	O
strongly	O
induced	O
.	O

This	O
was	O
followed	O
by	O
apparent	O
apoptosis	O
,	O
and	O
both	O
processes	O
were	O
specifically	O
inhibited	O
by	O
the	O
gp34	B-protein
-specific	O
neutralizing	B-protein
monoclonal	I-protein
antibody	I-protein
5A8	I-protein
.	O

Endogenous	O
TNF	B-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
TNF-beta	B-protein
production	O
were	O
not	O
involved	O
in	O
the	O
enhanced	O
HIV-1	O
production	O
.	O

Furthermore	O
,	O
enhanced	O
HIV-1	O
transcription	O
in	O
gp34	B-protein
-stimulated	O
ACH-2/OX40	B-cell_line
cells	I-cell_line
was	O
dependent	O
on	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
and	O
the	O
OX40-gp34	O
interaction	O
activated	O
NF-kappa	B-protein
B	I-protein
consisting	O
of	O
p50	B-protein
and	I-protein
p65	I-protein
subunits	I-protein
.	O

When	O
primary	O
activated	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
acutely	O
infected	O
with	O
HIV-1	O
(	O
NL4-3	O
)	O
(	O
CXCR4-using	B-cell_line
T-cell-line-tropic	I-cell_line
)	O
were	O
cocultured	O
with	O
PFA-fixed	O
gp34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
human	I-cell_type
T-cell	I-cell_type
leukemia	O
virus	O
type	O
1-bearing	O
MT-2	B-cell_line
cells	I-cell_line
or	O
SV-T2/gp34	B-cell_line
cells	I-cell_line
,	O
HIV-1	O
production	O
was	O
also	O
markedly	O
enhanced	O
.	O

The	O
enhancement	O
was	O
again	O
significantly	O
inhibited	O
by	O
5A8	B-protein
.	O

The	O
present	O
study	O
first	O
shows	O
that	O
OX40-gp34	O
interaction	O
stimulates	O
HIV-1	O
expression	O
and	O
suggests	O
that	O
OX40	O
triggering	O
by	O
gp34	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
enhancing	O
HIV-1	O
production	O
in	O
both	O
acutely	O
and	O
latently	O
infected	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vivo	O
.	O

JOURNAL	NULL
or	NULL
ViRoLOGY	NULL
,	NULL
Aug.	NULL
2001	NULL
,	NULL
p.	NULL
6748-6757	NULL
0022-538	NULL
%	NULL
X/01/	NULL
$	NULL
04.00+0	NULL
-	NULL
DOI	NULL
:	NULL
10.1128/JV1.75.15.6748-6757.2001	NULL
Vol	NULL
.	NULL

75	NULL
,	NULL
No	NULL
.	NULL

15	NULL
Copyright	NULL
©	NULL
2001	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

OX40	NULL
Stimulation	NULL
by	NULL
gp34/OX40	NULL
Ligand	NULL
Enhances	NULL
Productive	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
Infection	NULL
YOSHIAKI	NULL
TAKAHASHI	NULL
,	NULL
*	NULL
YUETSU	NULL
TANAKA	NULL
,	NULL
*	NULL
ATSUYA	NULL
YAMASHITA	NULL
,	NULL
``	NULL
YOSHIO	NULL
KOYANAGI	NULL
MASATAKA	NULL
NAKAMURA	NULL
,	NULL
*	NULL
anp	NULL
NAOKI	NULL
YAMAMOTO	NULL
'	NULL
!	NULL

*	NULL
Departments	NULL
of	NULL
Microbiology	NULL
and	NULL
Molecular	NULL
Virology	NULL
,	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Tokyo	NULL
Medical	NULL
and	NULL
Dental	NULL
University	NULL
,	NULL
Tokyo	NULL
113-8519	NULL
,	NULL
Department	NULL
of	NULL
Infectious	NULL
Disease	NULL
and	NULL
Immunology	NULL
,	NULL
Okinawa-Asia	NULL
Research	NULL
Center	NULL
of	NULL
Medical	NULL
Science	NULL
,	NULL
Faculty	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
The	NULL
Ryukyus	NULL
,	NULL
Okinawa	NULL
903-0215	NULL
,	NULL
``	NULL
Department	NULL
of	NULL
Virology	NULL
,	NULL
Tohoku	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Sendai	NULL
980-8575	NULL
,	NULL
``	NULL
and	NULL
Human	NULL
Gene	NULL
Sciences	NULL
Center	NULL
,	NULL
Tokyo	NULL
Medical	NULL
and	NULL
Dental	NULL
University	NULL
,	NULL
Tokyo	NULL
113-8510	NULL
,	NULL
*	NULL
Japan	NULL
Received	NULL
2	NULL
November	NULL
2000/Accepted	NULL
20	NULL
April	NULL
2001	NULL
OX40	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
LNF	NULL
)	NULL
receptor	NULL
superfamily	NULL
and	NULL
known	NULL
to	NULL
be	NULL
an	NULL
important	NULL
costimulatory	NULL
molecule	NULL
expressed	NULL
on	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
costimulation	NULL
of	NULL
OX40	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
infection	NULL
by	NULL
its	NULL
natural	NULL
ligand	NULL
,	NULL
gp34	NULL
,	NULL
the	NULL
OX4O-transfected	NULL
ACH-2	NULL
cell	NULL
line	NULL
,	NULL
ACH-2/0X40	NULL
,	NULL
chronically	NULL
infected	NULL
with	NULL
HIV-1	NULL
,	NULL
was	NULL
cocultured	NULL
with	NULL
paraformaldehyde	NULL
(	NULL
PFA	NULL
)	NULL
-fixed	NULL
gp34-transfected	NULL
mouse	NULL
cell	NULL
line	NULL
,	NULL
SV-T2/gp34	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
that	NULL
HIV-1	NULL
production	NULL
was	NULL
strongly	NULL
induced	NULL
.	NULL

This	NULL
was	NULL
followed	NULL
by	NULL
apparent	NULL
apoptosis	NULL
,	NULL
and	NULL
both	NULL
processes	NULL
were	NULL
specifically	NULL
inhibited	NULL
by	NULL
the	NULL
gp34-specific	NULL
neutralizing	NULL
monoclonal	NULL
antibody	NULL
5A8	NULL
.	NULL

Endogenous	NULL
TNF	NULL
alpha	NULL
(	NULL
TNF-	NULL
«	NULL
)	NULL
and	NULL
TNF-fB	NULL
production	NULL
were	NULL
not	NULL
involved	NULL
in	NULL
the	NULL
enhanced	NULL
HIV-1	NULL
production	NULL
.	NULL

Furthermore	NULL
,	NULL
enhanced	NULL
HIV-1	NULL
transcription	NULL
in	NULL
gp34-stimulated	NULL
ACH-2/0X40	NULL
cells	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
B	NULL
site	NULL
of	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
,	NULL
and	NULL
the	NULL
OX40-gp34	NULL
interaction	NULL
activated	NULL
consisting	NULL
of	NULL
p50	NULL
and	NULL
p65	NULL
subunits	NULL
.	NULL

When	NULL
primary	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
acutely	NULL
infected	NULL
with	NULL
,	NULL
,	NULL
(	NULL
CXCR4-using	NULL
T-cell-line-tropic	NULL
)	NULL
were	NULL
cocultured	NULL
with	NULL
PFA-fixed	NULL
gp34*	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1-bearing	NULL
MT-2	NULL
cells	NULL
or	NULL
SV-T2/gp34	NULL
cells	NULL
,	NULL
HIV-1	NULL
production	NULL
was	NULL
also	NULL
markedly	NULL
enhanced	NULL
.	NULL

The	NULL
enhancement	NULL
was	NULL
again	NULL
significantly	NULL
inhibited	NULL
by	NULL
5A8	NULL
.	NULL

The	NULL
present	NULL
study	NULL
first	NULL
shows	NULL
that	NULL
OX40-gp34	NULL
interaction	NULL
stimulates	NULL
HIV-1	NULL
expression	NULL
and	NULL
suggests	NULL
that	NULL
OX40	NULL
triggering	NULL
by	NULL
gp34	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
enhancing	NULL
HIV-1	NULL
production	NULL
in	NULL
both	NULL
acutely	NULL
and	NULL
latently	NULL
infected	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

Interaction	NULL
between	NULL
molecules	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
(	NULL
TNFR	NULL
)	NULL
superfamily	NULL
,	NULL
including	NULL
TNFRI	NULL
(	NULL
CD120a	NULL
)	NULL
,	NULL
TNFRII	NULL
(	NULL
CD120b	NULL
)	NULL
,	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
,	NULL
CD40	NULL
,	NULL
CD30	NULL
,	NULL
CD27	NULL
,	NULL
4-1BB	NULL
(	NULL
CD137	NULL
)	NULL
,	NULL
and	NULL
OX40	NULL
(	NULL
CD134	NULL
)	NULL
,	NULL
and	NULL
their	NULL
ligand	NULL
molecule	NULL
superfamily	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
costimulate	NULL
a	NULL
variety	NULL
of	NULL
cellular	NULL
responses	NULL
,	NULL
such	NULL
as	NULL
cell	NULL
growth	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
programmed	NULL
cell	NULL
death	NULL
(	NULL
apoptosis	NULL
)	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Human	NULL
OX40	NULL
was	NULL
identified	NULL
as	NULL
a	NULL
cell	NULL
surface	NULL
type	NULL
I	NULL
transmembrane	NULL
glycoprotein	NULL
antigen	NULL
of	NULL
50	NULL
kDa	NULL
,	NULL
whose	NULL
expression	NULL
is	NULL
limited	NULL
to	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Its	NULL
natural	NULL
ligand	NULL
,	NULL
gp34/human	NULL
OX40	NULL
ligand	NULL
(	NULL
OX40L	NULL
)	NULL
,	NULL
belongs	NULL
to	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
superfamily	NULL
,	NULL
including	NULL
TNF	NULL
,	NULL
FasL	NULL
,	NULL
CD4O0L	NULL
,	NULL
CD30L	NULL
,	NULL
CD27L	NULL
,	NULL
and	NULL
4-1BBL	NULL
.	NULL

Gp34	NULL
was	NULL
originally	NULL
identified	NULL
as	NULL
a	NULL
type	NULL
II	NULL
transmembrane	NULL
glycoprotein	NULL
of	NULL
34	NULL
kDa	NULL
expressed	NULL
on	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
-infected	NULL
T-cell	NULL
lines	NULL
and	NULL
induced	NULL
by	NULL
the	NULL
transactivator	NULL
p40	NULL
``	NULL
*	NULL
of	NULL
HTLV-1	NULL
(	NULL
26	NULL
,	NULL
40	NULL
)	NULL
.	NULL

Subsequently	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
gp34	NULL
was	NULL
the	NULL
ligand	NULL
for	NULL
human	NULL
OX40	NULL
(	NULL
3	NULL
,	NULL
11	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
gp34	NULL
is	NULL
limited	NULL
to	NULL
activated	NULL
normal	NULL
B	NULL
cells	NULL
and	NULL
activated	NULL
Epstein-Barr	NULL
virus-transformed	NULL
cells	NULL
(	NULL
11	NULL
,	NULL
28	NULL
)	NULL
,	NULL
vascular	NULL
endothelial	NULL
cells	NULL
(	NULL
VEC	NULL
)	NULL
(	NULL
16	NULL
)	NULL
,	NULL
and	NULL
a	NULL
subset	NULL
of	NULL
blood-derived	NULL
un-stimulated	NULL
or	NULL
CD4O0-stimulated	NULL
dendritic	NULL
cells	NULL
(	NULL
DC	NULL
)	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
OX40-gp34	NULL
interaction	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
bidirectional	NULL
signals	NULL
and	NULL
thus	NULL
is	NULL
implicated	NULL
in	NULL
various	NULL
immunolog-	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Departments	NULL
of	NULL
Microbiology	NULL
and	NULL
Molecular	NULL
Virology	NULL
,	NULL
Tokyo	NULL
Medical	NULL
and	NULL
Dental	NULL
University	NULL
,	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
1-5-45	NULL
Yushima	NULL
,	NULL
Bunkyo-ku	NULL
,	NULL
Tokyo	NULL
113-8519	NULL
,	NULL
Japan	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
813	NULL
)	NULL
5803-5178	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
813	NULL
)	NULL
5803-0124	NULL
.	NULL

E-mail	NULL
:	NULL
yamamoto.mmb	NULL
@	NULL
tmd.ac.jp	NULL
.	NULL

6748	NULL
ical	NULL
responses	NULL
.	NULL

(	NULL
i	NULL
)	NULL
For	NULL
example	NULL
,	NULL
gp34	NULL
on	NULL
DC	NULL
and	NULL
gp34	NULL
transfectants	NULL
provided	NULL
a	NULL
costimulatory	NULL
signal	NULL
to	NULL
OX40*	NULL
helper	NULL
T	NULL
cells	NULL
,	NULL
resulting	NULL
in	NULL
increased	NULL
proliferation	NULL
,	NULL
cytokine	NULL
production	NULL
,	NULL
and	NULL
preferential	NULL
differentiation	NULL
of	NULL
naive	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
type	NULL
2	NULL
helper	NULL
phenotype	NULL
.	NULL

Simultaneously	NULL
,	NULL
ligation	NULL
of	NULL
gp34	NULL
on	NULL
human	NULL
DC	NULL
by	NULL
OX4O0	NULL
enhanced	NULL
their	NULL
maturation	NULL
and	NULL
production	NULL
of	NULL
cytokines	NULL
(	NULL
3	NULL
,	NULL
11	NULL
,	NULL
30	NULL
,	NULL
31	NULL
)	NULL
:	NULL
(	NULL
ii	NULL
)	NULL
gp34	NULL
expressed	NULL
on	NULL
activated	NULL
B	NULL
cells	NULL
can	NULL
receive	NULL
a	NULL
signal	NULL
from	NULL
OX40	NULL
on	NULL
helper	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
resulted	NULL
in	NULL
B-cell	NULL
proliferation	NULL
and	NULL
immunoglobulin	NULL
secretion	NULL
(	NULL
28	NULL
)	NULL
;	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
the	NULL
OX40/gp34	NULL
system	NULL
directly	NULL
mediated	NULL
the	NULL
adhesion	NULL
of	NULL
OX40*	NULL
T	NULL
cells	NULL
to	NULL
gp34	NULL
``	NULL
*	NULL
human	NULL
umbilical	NULL
vein	NULL
endothelial	NULL
cells	NULL
(	NULL
HUVEC	NULL
)	NULL
(	NULL
16	NULL
)	NULL
,	NULL
and	NULL
c-jun	NULL
m-RNA	NULL
was	NULL
induced	NULL
in	NULL
*	NULL
HUVEC	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
showed	NULL
that	NULL
some	NULL
members	NULL
of	NULL
the	NULL
TNF/TNFR	NULL
superfamily	NULL
play	NULL
important	NULL
roles	NULL
in	NULL
enhancing	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
infection	NULL
:	NULL
(	NULL
i	NULL
)	NULL
TNF	NULL
alpha	NULL
(	NULL
TNF-a	NULL
)	NULL
enhances	NULL
HIV-1	NULL
replication	NULL
by	NULL
directly	NULL
increasing	NULL
its	NULL
transcription	NULL
level	NULL
through	NULL
induction	NULL
of	NULL
NF-kB	NULL
in	NULL
T-cell	NULL
lines	NULL
(	NULL
8	NULL
,	NULL
32	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
CD30	NULL
triggering	NULL
stimulated	NULL
HIV-1	NULL
expression	NULL
through	NULL
an	NULL
NF-	NULL
«	NULL
B-dependent	NULL
pathway	NULL
in	NULL
the	NULL
chronically	NULL
HIV-1-infected	NULL
T-cell	NULL
line	NULL
ACH-2	NULL
(	NULL
4	NULL
)	NULL
,	NULL
and	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
HIV-1-positive	NULL
individuals	NULL
also	NULL
demonstrated	NULL
enhanced	NULL
HIV-1	NULL
production	NULL
by	NULL
CD30	NULL
stimulation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-CD3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MAb	NULL
)	NULL
(	NULL
21	NULL
)	NULL
;	NULL
(	NULL
iii	NULL
)	NULL
cross-linking	NULL
of	NULL
4-1BB	NULL
with	NULL
agonistic	NULL
MAb	NULL
significantly	NULL
enhanced	NULL
HIV-1	NULL
replication	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
HIV-1*	NULL
individuals	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-CD3	NULL
MAb	NULL
(	NULL
46	NULL
)	NULL
;	NULL
and	NULL
(	NULL
iv	NULL
)	NULL
CD40	NULL
stimulation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
interleukin-4	NULL
(	NULL
IL-4	NULL
)	NULL
and	NULL
IL-2	NULL
upregulated	NULL
HIV	NULL
replication	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
activation	NULL
of	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
TNFR	NULL
superfamily	NULL
proteins	NULL
,	NULL
including	NULL
TNFRI	NULL
,	NULL
TNFRII	NULL
,	NULL
CD30	NULL
,	NULL
4-1BB	NULL
,	NULL
CD40	NULL
,	NULL
and	NULL
OX40	NULL
,	NULL
recruited	NULL
several	NULL
members	NULL
of	NULL
signal	NULL
transducers	NULL
called	NULL
TNFR-associated	NULL
factors	NULL
(	NULL
TRAFs	NULL
)	NULL
,	NULL
and	NULL
some	NULL
members	NULL
of	NULL
the	NULL
TRAF	NULL
family	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
(	NULL
1	NULL
,	NULL
17	NULL
,	NULL
19	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
explored	NULL
the	NULL
effect	NULL
of	NULL
OX40	NULL
costimulation	NULL
by	NULL
gp34	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
stimulation	NULL
of	NULL
acutely	NULL
and	NULL
chronically	NULL
HIV-l-infected	NULL
T	NULL
cells	NULL
through	NULL
OX40	NULL
by	NULL
gp34	NULL
``	NULL
HTLV-1	NULL
*	NULL
T	NULL
cells	NULL
or	NULL
gp34-transfected	NULL
cells	NULL
,	NULL
respectively	NULL
,	NULL
significantly	NULL
enhances	NULL
HIV-1	NULL
expression	NULL
in	NULL
vitro	NULL
.	NULL

Our	NULL
findings	NULL
suggest	NULL
that	NULL
OX40-gp34	NULL
interaction	NULL
in	NULL
vivo	NULL
in	NULL
HIV-1-infected	NULL
patients	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
enhancement	NULL
of	NULL
productive	NULL
infection	NULL
of	NULL
HIV-1	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
.	NULL

ACH-2	NULL
cell	NULL
line	NULL
(	NULL
7	NULL
)	NULL
was	NULL
cultured	NULL
in	NULL
RPM1	NULL
1640	NULL
medium	NULL
(	NULL
Nikken	NULL
Biolaboratory	NULL
,	NULL
Kyoto	NULL
,	NULL
Japan	NULL
)	NULL
containing	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
;	NULL
JRH	NULL
Biosciences	NULL
,	NULL
Lenexa	NULL
,	NULL
Kans	NULL
.	NULL
)	NULL

,	NULL
2	NULL
mM	NULL
r-glutamine	NULL
,	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
100	NULL
jg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
(	NULL
hereinafter	NULL
called	NULL
RPM1-CM	NULL
)	NULL
at	NULL
37°C	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

The	NULL
SV-T2	NULL
cell	NULL
line	NULL
that	NULL
originated	NULL
from	NULL
murine	NULL
embryo	NULL
musculus	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
Human	NULL
Science	NULL
Research	NULL
Resources	NULL
Bank	NULL
(	NULL
Osaka	NULL
,	NULL
Japan	NULL
)	NULL
,	NULL
and	NULL
cultured	NULL
in	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
(	NULL
DMEM	NULL
;	NULL
Nikken	NULL
Biolaboratory	NULL
)	NULL
containing	NULL
10	NULL
%	NULL
FBS	NULL
,	NULL
4	NULL
mM	NULL
r-glutamine	NULL
,	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
100	NULL
ug	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
(	NULL
hereinafter	NULL
called	NULL
DME-CM	NULL
)	NULL
.	NULL

To	NULL
establish	NULL
transfectants	NULL
of	NULL
ACH-2	NULL
cells	NULL
expressing	NULL
OX40	NULL
,	NULL
ACH-2/0X40	NULL
,	NULL
20	NULL
ug	NULL
of	NULL
the	NULL
OX40	NULL
plasmids	NULL
(	NULL
pCAGIPuro/OX40	NULL
)	NULL
were	NULL
linearized	NULL
by	NULL
digestion	NULL
with	NULL
Puel	NULL
,	NULL
suspended	NULL
in	NULL
K-PBS	NULL
(	NULL
120	NULL
mM	NULL
KCI	NULL
,	NULL
30	NULL
mM	NULL
NaCl	NULL
,	NULL
8	NULL
mM	NULL
Na	NULL
,	NULL
HPO	NULL
,	NULL
,	NULL
1.5	NULL
mM	NULL
KH	NULL
;	NULL
PO	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
MgCl	NULL
;	NULL
)	NULL
,	NULL
and	NULL
introduced	NULL
into	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
of	NULL
the	NULL
ACH-2	NULL
cell	NULL
line	NULL
by	NULL
an	NULL
electroporation	NULL
method	NULL
using	NULL
the	NULL
Gene	NULL
Pulser	NULL
II	NULL
(	NULL
Bio-Rad	NULL
Laboratories	NULL
,	NULL
Hercules	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

ACH-2/mock	NULL
cells	NULL
were	NULL
also	NULL
produced	NULL
by	NULL
electroporation	NULL
of	NULL
lineared	NULL
pCAGIPuro	NULL
vector	NULL
without	NULL
an	NULL
insert	NULL
.	NULL

These	NULL
transfectants	NULL
were	NULL
suspended	NULL
at	NULL
1	NULL
X	NULL
10°	NULL
to	NULL
2	NULL
x	NULL
10°	NULL
cells/ml	NULL
in	NULL
RPMI-CM	NULL
,	NULL
dispensed	NULL
at	NULL
5	NULL
X	NULL
10	NULL
``	NULL
to	NULL
10	NULL
x	NULL
10°	NULL
cells/well	NULL
in	NULL
24-well	NULL
plates	NULL
,	NULL
and	NULL
cultured	NULL
for	NULL
4	NULL
days	NULL
,	NULL
selected	NULL
by	NULL
RPMI-CM	NULL
containing	NULL
0.2	NULL
jpg	NULL
of	NULL
puromycin	NULL
(	NULL
Clontech	NULL
Laboratories	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
Calif.	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
then	NULL
cultured	NULL
in	NULL
1	NULL
pg	NULL
of	NULL
puromycin	NULL
per	NULL
ml	NULL
thereafter	NULL
.	NULL

Selected	NULL
ACH-2/0X40	NULL
cells	NULL
were	NULL
examined	NULL
for	NULL
spontancous	NULL
release	NULL
of	NULL
HIV-1	NULL
by	NULL
measuring	NULL
the	NULL
p24	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
.	NULL

Ten	NULL
cells	NULL
producing	NULL
low	NULL
levels	NULL
of	NULL
p24	NULL
were	NULL
selected	NULL
for	NULL
further	NULL
studies	NULL
.	NULL

Their	NULL
OX40	NULL
and	NULL
gp34	NULL
expression	NULL
were	NULL
examined	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

Similarly	NULL
,	NULL
gp34-expressing	NULL
SV-T2	NULL
cells	NULL
,	NULL
SV-T2/gp34	NULL
cells	NULL
,	NULL
and	NULL
SV-T2/mock	NULL
cells	NULL
were	NULL
established	NULL
and	NULL
cultured	NULL
in	NULL
DME-CM	NULL
containing	NULL
2	NULL
ug	NULL
of	NULL
puromycin	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
gp34	NULL
expression	NULL
were	NULL
determined	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

Preparation	NULL
of	NULL
primary	NULL
CD4*	NULL
T	NULL
cells	NULL
was	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
38	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
were	NULL
isolated	NULL
by	NULL
density	NULL
gradient	NULL
centrifugation	NULL
with	NULL
Ficoll-Hypaque	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
from	NULL
the	NULL
heparinized	NULL
peripheral	NULL
blood	NULL
of	NULL
healthy	NULL
donors	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
adherent-cell-depleted	NULL
PBMC	NULL
by	NULL
positive	NULL
selection	NULL
with	NULL
immunomagnetic	NULL
beads	NULL
conjugated	NULL
to	NULL
anti-CD4	NULL
antibody	NULL
(	NULL
Ab	NULL
;	NULL
Dynal	NULL
,	NULL
Oslo	NULL
,	NULL
Norway	NULL
)	NULL
.	NULL

The	NULL
purified	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
10°	NULL
cells/ml	NULL
)	NULL
in	NULL
RPMI-CM	NULL
with	NULL
50	NULL
U	NULL
of	NULL
recombinant	NULL
human	NULL
IL-2	NULL
(	NULL
rhIL-2	NULL
;	NULL
Shionogi	NULL
Pharmaceutical	NULL
,	NULL
Osaka	NULL
,	NULL
Japan	NULL
)	NULL
and	NULL
20	NULL
ng	NULL
of	NULL
rhIL-4	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
Minn.	NULL
)	NULL
per	NULL
ml	NULL
were	NULL
plated	NULL
in	NULL
12-well	NULL
plates	NULL
coated	NULL
with	NULL
anti-human	NULL
CD3	NULL
MAb	NULL
(	NULL
OKT-3	NULL
;	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

and	NULL
then	NULL
incubated	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
incubator	NULL
.	NULL

On	NULL
day	NULL
3	NULL
,	NULL
cells	NULL
in	NULL
the	NULL
cultures	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
fresh	NULL
RPMI-CM	NULL
with	NULL
rhIL-2	NULL
and	NULL
rhIL-4	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
and	NULL
then	NULL
restimulated	NULL
by	NULL
immobilized	NULL
anti-CD3	NULL
MAb	NULL
.	NULL

On	NULL
day	NULL
6	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
fresh	NULL
RPMI-CM	NULL
with	NULL
rhIL-2	NULL
and	NULL
thIL-4	NULL
at	NULL
(	NULL
5	NULL
%	NULL
10°	NULL
cells/ml	NULL
)	NULL
and	NULL
then	NULL
were	NULL
plated	NULL
without	NULL
immobilized	NULL
anti-human	NULL
CD3	NULL
MAb	NULL
.	NULL

These	NULL
primary	NULL
CD4*	NULL
T-cell	NULL
cultures	NULL
were	NULL
harvested	NULL
on	NULL
day	NULL
8	NULL
and	NULL
then	NULL
used	NULL
as	NULL
targets	NULL
for	NULL
HIV-1	NULL
infection	NULL
.	NULL

The	NULL
HTLV-1-bearing	NULL
MT-2	NULL
cell	NULL
line	NULL
(	NULL
27	NULL
)	NULL
was	NULL
cultured	NULL
in	NULL
RPMI-CM	NULL
at	NULL
37°C	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

Sf9	NULL
insect	NULL
cells	NULL
(	NULL
Invitrogen	NULL
,	NULL
Carlsbad	NULL
,	NULL
Calif.	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
TC-100	NULL
insect	NULL
medium	NULL
(	NULL
GIBCO-BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

including	NULL
10	NULL
%	NULL
FBS	NULL
,	NULL
100	NULL
pg	NULL
of	NULL
kana-mycin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
Tryptose	NULL
Phosphate	NULL
Broth	NULL
(	NULL
GIBCO-BRL	NULL
)	NULL
(	NULL
hereinafter	NULL
called	NULL
TC-100-CM	NULL
)	NULL
at	NULL
26.5°C	NULL
.	NULL

High	NULL
Five	NULL
insect	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
Sf-900	NULL
II	NULL
SFM	NULL
(	NULL
GIBCO-BRL	NULL
)	NULL
at	NULL
26.5°C	NULL
.	NULL

A	NULL
myeloma	NULL
cell	NULL
line	NULL
,	NULL
SP2/0-Ag14	NULL
(	NULL
Riken	NULL
Cell	NULL
Bank	NULL
,	NULL
Saitama	NULL
,	NULL
Japan	NULL
)	NULL
,	NULL
and	NULL
a	NULL
MOLT-4	NULL
cell	NULL
line	NULL
(	NULL
25	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
RPMI-CM	NULL
at	NULL
37°C	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

ENHANCED	NULL
HIV-1	NULL
PRODUCTION	NULL
BY	NULL
OX40	NULL
COSTIMULATION	NULL
-	NULL
6749	NULL
Preparation	NULL
of	NULL
soluble	NULL
OX40	NULL
.	NULL

Recombinant	NULL
soluble	NULL
OX40	NULL
was	NULL
generated	NULL
by	NULL
a	NULL
baculovirus	NULL
expression	NULL
system	NULL
.	NULL

The	NULL
Bac-N-Blue	NULL
Transfection	NULL
Kit	NULL
(	NULL
Invitrogen	NULL
)	NULL
,	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
extracellular	NULL
portion	NULL
of	NULL
OX40	NULL
(	NULL
nucleotides	NULL
85	NULL
to	NULL
648	NULL
tagged	NULL
with	NULL
BamHI	NULL
and	NULL
HindIII	NULL
sites	NULL
)	NULL
was	NULL
amplified	NULL
by	NULL
PCR	NULL
and	NULL
ligated	NULL
into	NULL
the	NULL
peDNA3.1	NULL
(	NULL
-	NULL
)	NULL
/Myc-His	NULL
A	NULL
vector	NULL
(	NULL
Invitrogen	NULL
)	NULL
;	NULL
after	NULL
that	NULL
,	NULL
the	NULL
portion	NULL
of	NULL
OX40-Myc-His	NULL
was	NULL
ligated	NULL
into	NULL
the	NULL
baculovirus	NULL
vector	NULL
,	NULL
pMclBac	NULL
A	NULL
vector	NULL
(	NULL
Invitrogen	NULL
)	NULL
.	NULL

Bac-N-Blue	NULL
DNA	NULL
and	NULL
pMelBac	NULL
A/OX40-Myc-His	NULL
vector	NULL
were	NULL
then	NULL
cotransfected	NULL
into	NULL
Sf9	NULL
cells	NULL
(	NULL
Invitrogen	NULL
)	NULL
using	NULL
SuperFect	NULL
transfection	NULL
reagent	NULL
(	NULL
Qiagen	NULL
,	NULL
Hilden	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

A	NULL
cloned	NULL
OX40-Myc-His	NULL
(	NULL
OX40-MH	NULL
)	NULL
-expressing	NULL
recombinant	NULL
baculovirus	NULL
(	NULL
P1	NULL
viral	NULL
stock	NULL
)	NULL
was	NULL
infected	NULL
into	NULL
Sf9	NULL
cells	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
(	NULL
MOI	NULL
)	NULL
of	NULL
0.1	NULL
in	NULL
TC-100-CM	NULL
.	NULL

After	NULL
5	NULL
days	NULL
,	NULL
the	NULL
cells	NULL
and	NULL
supernatants	NULL
were	NULL
harvested	NULL
(	NULL
P2	NULL
viral	NULL
stock	NULL
)	NULL
.	NULL

Thereafter	NULL
,	NULL
this	NULL
viral	NULL
stock	NULL
was	NULL
used	NULL
to	NULL
infect	NULL
High	NULL
Five	NULL
cells	NULL
(	NULL
Invitrogen	NULL
)	NULL
at	NULL
an	NULL
MOI	NULL
of	NULL
50	NULL
in	NULL
Sf-900	NULL
II	NULL
SFM	NULL
and	NULL
,	NULL
after	NULL
5	NULL
days	NULL
,	NULL
the	NULL
supernatants	NULL
were	NULL
harvested	NULL
.	NULL

The	NULL
recombinant	NULL
fusion	NULL
protein	NULL
was	NULL
purified	NULL
by	NULL
Ni-nitrilotriacetic	NULL
acid-agarose	NULL
(	NULL
Qiagen	NULL
)	NULL
and	NULL
was	NULL
confirmed	NULL
by	NULL
silver	NULL
staining	NULL
and	NULL
Western	NULL
blotting	NULL
.	NULL

Generation	NULL
of	NULL
MAb	NULL
against	NULL
human	NULL
OX40	NULL
and	NULL
other	NULL
Abs	NULL
.	NULL

BALB/c	NULL
mice	NULL
were	NULL
immunized	NULL
subcutaneously	NULL
and	NULL
intramuscularly	NULL
with	NULL
100	NULL
ug	NULL
of	NULL
recombinant	NULL
fusion	NULL
protein	NULL
,	NULL
OX40-MH	NULL
,	NULL
emulsified	NULL
with	NULL
Freund	NULL
complete	NULL
adjuvant	NULL
(	NULL
Wako	NULL
,	NULL
Osaka	NULL
,	NULL
Japan	NULL
)	NULL
,	NULL
and	NULL
with	NULL
Freund	NULL
's	NULL
incomplete	NULL
adjuvant	NULL
(	NULL
Wako	NULL
)	NULL
two	NULL
more	NULL
times	NULL
at	NULL
2-week	NULL
intervals	NULL
.	NULL

The	NULL
sensitized	NULL
spleen	NULL
cells	NULL
were	NULL
fused	NULL
with	NULL
a	NULL
mouse	NULL
myeloma	NULL
cell	NULL
line	NULL
,	NULL
SP2/0-Ag14	NULL
,	NULL
using	NULL
polyethylene	NULL
glycol	NULL
1500	NULL
(	NULL
Roche	NULL
Diagnostics	NULL
,	NULL
Mann-heim	NULL
,	NULL
Germany	NULL
)	NULL
3	NULL
days	NULL
after	NULL
a	NULL
final	NULL
booster	NULL
immunization	NULL
of	NULL
OX40-MH	NULL
alone	NULL
by	NULL
the	NULL
intravenous	NULL
or	NULL
the	NULL
intraperitoneal	NULL
route	NULL
.	NULL

After	NULL
selection	NULL
in	NULL
RPMI-CM	NULL
containing	NULL
hypoxanthine	NULL
,	NULL
aminopterin	NULL
,	NULL
and	NULL
thymidine	NULL
(	NULL
Roche	NULL
Diagnostics	NULL
)	NULL
,	NULL
hybrid-omas	NULL
producing	NULL
MAb	NULL
reactive	NULL
with	NULL
human	NULL
OX40	NULL
were	NULL
screened	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
and	NULL
Western	NULL
blotting	NULL
using	NULL
the	NULL
OX40*	NULL
MT-2	NULL
cell	NULL
line	NULL
and	NULL
the	NULL
OX40~	NULL
MOLT-4	NULL
cell	NULL
line	NULL
(	NULL
16	NULL
)	NULL
and	NULL
then	NULL
cloned	NULL
by	NULL
limiting	NULL
dilution	NULL
.	NULL

B-7B5	NULL
,	NULL
newly	NULL
generated	NULL
in	NULL
this	NULL
study	NULL
,	NULL
was	NULL
typed	NULL
as	NULL
immunoglobulin	NULL
G1	NULL
(	NULL
IgG1	NULL
)	NULL
and	NULL
by	NULL
the	NULL
Mouse	NULL
MonoAb	NULL
ID/SP	NULL
Kit	NULL
(	NULL
Zymed	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
Calif.	NULL
)	NULL
and	NULL
was	NULL
also	NULL
labeled	NULL
by	NULL
CyS5	NULL
Ab	NULL
labeled	NULL
kit	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
for	NULL
flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

Other	NULL
MAbs	NULL
used	NULL
were	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
anti-gp34	NULL
MAb	NULL
(	NULL
TAG-34	NULL
)	NULL
(	NULL
40	NULL
)	NULL
,	NULL
CyS-conjugated	NULL
negative	NULL
control	NULL
mouse	NULL
IgG1	NULL
(	NULL
TAXY-8	NULL
)	NULL
(	NULL
42	NULL
)	NULL
,	NULL
FITC-conjugated	NULL
negative	NULL
control	NULL
mouse	NULL
IgG1	NULL
(	NULL
DAK-GO1	NULL
;	NULL
Dako	NULL
,	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
)	NULL
,	NULL
anti-human	NULL
OX40	NULL
MAb	NULL
(	NULL
Ber	NULL
Act	NULL
35	NULL
;	NULL
Ancell	NULL
,	NULL
Bayport	NULL
,	NULL
Minn.	NULL
)	NULL
,	NULL
anti-myc	NULL
MAb	NULL
(	NULL
Invitrogen	NULL
)	NULL
,	NULL
anti-Fas	NULL
MAb	NULL
(	NULL
CH-11	NULL
;	NULL
MBL	NULL
,	NULL
Nagoya	NULL
,	NULL
Japan	NULL
)	NULL
,	NULL
gp34-neutralizing	NULL
MAb	NULL
(	NULL
5A8	NULL
)	NULL
(	NULL
16	NULL
,	NULL
44	NULL
)	NULL
,	NULL
TNF-o-neutralizing	NULL
MAb	NULL
(	NULL
1825.121	NULL
;	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
,	NULL
TNF-B-neutralizing	NULL
MAb	NULL
(	NULL
5802.21	NULL
;	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
,	NULL
FasL-neutralizing	NULL
MAb	NULL
(	NULL
NOK2	NULL
;	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
,	NULL
and	NULL
negative	NULL
control	NULL
IgG1	NULL
(	NULL
MET-3	NULL
)	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Alkaline	NULL
phosphatase-conjugated	NULL
anti-mouse	NULL
IgG	NULL
Ab	NULL
and	NULL
rabbit	NULL
Abs	NULL
to	NULL
p50	NULL
(	NULL
sc-7178	NULL
X	NULL
)	NULL
,	NULL
p52	NULL
(	NULL
sc-298	NULL
X	NULL
)	NULL
,	NULL
p63	NULL
(	NULL
sc-372	NULL
X	NULL
)	NULL
,	NULL
c-Rel	NULL
(	NULL
sc-70	NULL
X	NULL
)	NULL
,	NULL
and	NULL
Rel-B	NULL
(	NULL
sc-226	NULL
X	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Control	NULL
rabbit	NULL
Ab	NULL
was	NULL
purchased	NULL
from	NULL
Diaclone	NULL
Research	NULL
(	NULL
Besagn	NULL
Cedex	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Plasmids	NULL
.	NULL

Expression	NULL
vectors	NULL
of	NULL
human	NULL
OX40	NULL
(	NULL
pCAGIPuro/OX40	NULL
)	NULL
and	NULL
gp34	NULL
(	NULL
pCAGIPuro/gp34	NULL
)	NULL
were	NULL
constructed	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
coding	NULL
sequences	NULL
of	NULL
human	NULL
OX40	NULL
(	NULL
20	NULL
)	NULL
or	NULL
gp34	NULL
(	NULL
26	NULL
)	NULL
were	NULL
amplified	NULL
by	NULL
the	NULL
PCR	NULL
method	NULL
.	NULL

For	NULL
human	NULL
OX40	NULL
we	NULL
used	NULL
the	NULL
primers	NULL
(	NULL
forward	NULL
,	NULL
nucleotides	NULL
6	NULL
to	NULL
35	NULL
of	NULL
human	NULL
OX40	NULL
cDNA	NULL
tagged	NULL
with	NULL
an	NULL
XhoI	NULL
site	NULL
;	NULL
reverse	NULL
,	NULL
nucleotides	NULL
808	NULL
to	NULL
839	NULL
tagged	NULL
with	NULL
an	NULL
NofT	NULL
site	NULL
)	NULL
and	NULL
pKU2-OX40-11	NULL
vector	NULL
for	NULL
template	NULL
(	NULL
15	NULL
)	NULL
.	NULL

For	NULL
gp34	NULL
we	NULL
used	NULL
the	NULL
primers	NULL
(	NULL
forward	NULL
,	NULL
nucleotides	NULL
37	NULL
to	NULL
69	NULL
of	NULL
gp34	NULL
cDNA	NULL
tagged	NULL
with	NULL
an	NULL
Xhol	NULL
site	NULL
;	NULL
reverse	NULL
,	NULL
nucleotides	NULL
554	NULL
to	NULL
588	NULL
tagged	NULL
with	NULL
an	NULL
Nof	NULL
!	NULL

site	NULL
)	NULL
and	NULL
pSGP34-1	NULL
vector	NULL
for	NULL
a	NULL
template	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Each	NULL
PCR	NULL
product	NULL
was	NULL
ligated	NULL
into	NULL
pGEM-T	NULL
vector	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
.	NULL

The	NULL
Xhol/NofI	NULL
fragments	NULL
of	NULL
human	NULL
OX40	NULL
and	NULL
gp34	NULL
were	NULL
each	NULL
subcloned	NULL
into	NULL
pCAGIPuro	NULL
expression	NULL
vector	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
H.	NULL
Niwa	NULL
,	NULL
Osaka	NULL
University	NULL
Medical	NULL
School	NULL
,	NULL
Osaka	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

A	NULL
series	NULL
of	NULL
reporter	NULL
plasmids	NULL
of	NULL
HIV-1	NULL
long-terminal-repeat	NULL
(	NULL
LTR	NULL
)	NULL
activity	NULL
were	NULL
constructed	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
3	NULL
'	NULL
LTR	NULL
fragment	NULL
of	NULL
the	NULL
(	NULL
Xhol-HindIII	NULL
,	NULL
nucleotides	NULL
8887	NULL
to	NULL
9663	NULL
)	NULL
was	NULL
inserted	NULL
into	NULL
the	NULL
XhoI	NULL
and	NULL
HindIII	NULL
sites	NULL
of	NULL
pGL3-Basic	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

The	NULL
deletion	NULL
mutant	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
in	NULL
HIV-1yy	NULL
,	NULL
.3	NULL
plasmid	NULL
(	NULL
36	NULL
)	NULL
was	NULL
also	NULL
inserted	NULL
.	NULL

These	NULL
plasmids	NULL
were	NULL
designated	NULL
as	NULL
pLTR-luc	NULL
and	NULL
pLTR-lucANF-	NULL
«	NULL
B	NULL
.	NULL

HIV-1	NULL
infection	NULL
and	NULL
p24	NULL
assay	NULL
.	NULL

Five	NULL
ACH-2/0X40	NULL
cell	NULL
groups	NULL
(	NULL
cell	NULL
groups	NULL
3	NULL
,	NULL
4	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
10	NULL
)	NULL
,	NULL
four	NULL
ACH-2/mock	NULL
cell	NULL
groups	NULL
(	NULL
cell	NULL
groups	NULL
2	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
,	NULL
and	NULL
ACH-2	NULL
cells	NULL
were	NULL
suspended	NULL
at	NULL
4	NULL
X	NULL
10°	NULL
cells/ml	NULL
in	NULL
RPMI-CM	NULL
and	NULL
dispensed	NULL
at	NULL
10°	NULL
cells/well	NULL
in	NULL
48-well	NULL
plates	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
cultures	NULL
were	NULL
stimulated	NULL
with	NULL
SV-T2/gp34	NULL
or	NULL
SV-T2/mock	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
cells/well	NULL
)	NULL
pretreated	NULL
with	NULL
4	NULL
%	NULL
PFA	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

TNF-a	NULL
(	NULL
2	NULL
ng/ml	NULL
;	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
and	NULL
TNF-B	NULL
(	NULL
10	NULL
ng/ml	NULL
;	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
were	NULL
added	NULL
as	NULL
controls	NULL
for	NULL
positive	NULL
stimulation	NULL
for	NULL
enhanced	NULL
HIV-1	NULL
expression	NULL
in	NULL
ACH-2	NULL
(	NULL
4	NULL
)	NULL
,	NULL
ACH-2/mock	NULL
,	NULL
and	NULL
ACH-2/0X40	NULL
cells	NULL
.	NULL

After	NULL
cultivation	NULL
for	NULL
3	NULL
days	NULL
,	NULL
cell-free	NULL
culture	NULL
supernatants	NULL
were	NULL
collected	NULL
for	NULL
measuring	NULL
HIV-1	NULL
p24	NULL
by	NULL
a	NULL
Lumipulse	NULL
(	NULL
Fujirebio	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

For	NULL
blocking	NULL
67530	NULL
TAKAHASHI	NULL
ET	NULL
AL	NULL
.	NULL

gp34-0X40	NULL
interaction	NULL
,	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
and	NULL
SV-T2/mock	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
or	NULL
without	NULL
5	NULL
,	NULL
1	NULL
,	NULL
0.2	NULL
,	NULL
or	NULL
0.04	NULL
g	NULL
of	NULL
anti-gp34	NULL
neutralizing	NULL
MAb	NULL
(	NULL
5A8	NULL
)	NULL
or	NULL
control	NULL
MAb	NULL
(	NULL
MET-3	NULL
)	NULL
per	NULL
ml	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

For	NULL
kinetic	NULL
studies	NULL
of	NULL
HIV-1	NULL
p24	NULL
expression	NULL
,	NULL
culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
at	NULL
various	NULL
time	NULL
points	NULL
.	NULL

To	NULL
exclude	NULL
an	NULL
involvement	NULL
of	NULL
TNF	NULL
in	NULL
enhanced	NULL
HIV-1	NULL
expression	NULL
in	NULL
ACH-2/0X40	NULL
cells	NULL
,	NULL
stimulator	NULL
cells	NULL
,	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
,	NULL
and	NULL
SV-T2/	NULL
mock	NULL
cells	NULL
,	NULL
exogencously	NULL
added	NULL
TNF-	NULL
«	NULL
and	NULL
TNF-B	NULL
were	NULL
pretreated	NULL
with	NULL
or	NULL
without	NULL
anti-human	NULL
TNF-	NULL
«	NULL
neutralizing	NULL
MAb	NULL
(	NULL
50	NULL
pg/ml	NULL
)	NULL
,	NULL
anti-human	NULL
TNF-neutralizing	NULL
MAb	NULL
(	NULL
5	NULL
pg/m1	NULL
)	NULL
,	NULL
or	NULL
control	NULL
MAb	NULL
(	NULL
MET	NULL
-3	NULL
,	NULL
50	NULL
g/m	NULL
!	NULL
)	NULL

for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
before	NULL
stimulation	NULL
.	NULL

The	NULL
culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
after	NULL
cultivation	NULL
for	NULL
3	NULL
days	NULL
.	NULL

Primary	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
wild-type	NULL
or	NULL
NF-	NULL
«	NULL
B	NULL
mutant	NULL
HIV-1ni4.3	NULL
(	NULL
45	NULL
)	NULL
at	NULL
an	NULL
MOI	NULL
of	NULL
0.002	NULL
and	NULL
were	NULL
cultured	NULL
at	NULL
5	NULL
%	NULL
10°	NULL
cells/ml	NULL
in	NULL
RPMI-CM	NULL
containing	NULL
50	NULL
U	NULL
of	NULL
rhIL-2	NULL
per	NULL
ml	NULL
in	NULL
a	NULL
12-well	NULL
plate	NULL
,	NULL
with	NULL
or	NULL
without	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
half	NULL
number	NULL
of	NULL
PFA-fixed	NULL
gp34*	NULL
HTLV-1-bearing	NULL
MT-2	NULL
cells	NULL
(	NULL
40	NULL
)	NULL
,	NULL
SV-T2/gp34	NULL
cells	NULL
,	NULL
or	NULL
SV-T2/mock	NULL
cells	NULL
pretreated	NULL
with	NULL
either	NULL
10	NULL
mg	NULL
of	NULL
anti-gp34	NULL
neutralizing	NULL
MAb	NULL
(	NULL
5A8	NULL
)	NULL
or	NULL
a	NULL
control	NULL
MAb	NULL
(	NULL
MET-3	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

On	NULL
day	NULL
3	NULL
,	NULL
4	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
after	NULL
HIV-1	NULL
infection	NULL
,	NULL
the	NULL
culture	NULL
supernatants	NULL
were	NULL
collected	NULL
for	NULL
p24	NULL
assay	NULL
.	NULL

Silver	NULL
staining	NULL
and	NULL
Western	NULL
blotting	NULL
.	NULL

The	NULL
fusion	NULL
protein	NULL
was	NULL
mixed	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
twofold-concentrated	NULL
sample	NULL
buffer	NULL
(	NULL
125	NULL
mM	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
6.8	NULL
;	NULL
4	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
[	NULL
SDS	NULL
]	NULL
;	NULL
20	NULL
%	NULL
glycerol	NULL
;	NULL
0.1	NULL
%	NULL
bromophenol	NULL
blue	NULL
)	NULL
,	NULL
including	NULL
8	NULL
%	NULL
2-mercaptocethanol	NULL
,	NULL
and	NULL
boiled	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
obtained	NULL
by	NULL
lysis	NULL
of	NULL
2	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
a	NULL
lysis	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
[	NULL
pH	NULL
8.0	NULL
]	NULL
containing	NULL
140	NULL
mM	NULL
NaCl	NULL
,	NULL
3	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
2	NULL
mM	NULL
phenyl-methylsulfony	NULL
]	NULL
fluoride	NULL
[	NULL
PMSF	NULL
]	NULL
,	NULL
and	NULL
0.5	NULL
%	NULL
Nonidet	NULL
P-40	NULL
)	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
,	NULL
followed	NULL
by	NULL
centrifugation	NULL
at	NULL
13,000	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
cell	NULL
lysates	NULL
were	NULL
mixed	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
twofold-concentrated	NULL
sample	NULL
buffer	NULL
without	NULL
2-mercaptocthanol	NULL
and	NULL
treated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Samples	NULL
were	NULL
fractionated	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
using	NULL
a	NULL
12.5	NULL
%	NULL
gel	NULL
.	NULL

The	NULL
fusion	NULL
protein	NULL
in	NULL
gel	NULL
was	NULL
stained	NULL
by	NULL
a	NULL
silver	NULL
staining	NULL
kit	NULL
(	NULL
Daiichi	NULL
Pure	NULL
Chemicals	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

A	NULL
part	NULL
of	NULL
the	NULL
sample	NULL
were	NULL
transferred	NULL
to	NULL
Clear	NULL
Blot	NULL
Membrane-P	NULL
(	NULL
Atto	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
in	NULL
transfer	NULL
buffer	NULL
(	NULL
25	NULL
mM	NULL
Tris	NULL
,	NULL
192	NULL
mM	NULL
glycine	NULL
,	NULL
1	NULL
%	NULL
ethanol	NULL
)	NULL
,	NULL
blocked	NULL
with	NULL
Block	NULL
Ace	NULL
(	NULL
Dainippon	NULL
Pharmaceutical	NULL
,	NULL
Osaka	NULL
,	NULL
Japan	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
the	NULL
primary	NULL
Abs	NULL
of	NULL
1	NULL
ug	NULL
of	NULL
anti-OX40	NULL
MAb	NULL
(	NULL
Ber	NULL
Act	NULL
35	NULL
or	NULL
B-7B5	NULL
)	NULL
,	NULL
0.2	NULL
ug	NULL
of	NULL
anti-mye	NULL
MAb	NULL
,	NULL
or	NULL
1	NULL
g	NULL
of	NULL
negative	NULL
control	NULL
MAb	NULL
per	NULL
ml	NULL
.	NULL

These	NULL
were	NULL
incubated	NULL
with	NULL
alkaline	NULL
phosphatase-conjugated	NULL
anti-mouse	NULL
immunoglobulin	NULL
G	NULL
(	NULL
IgG	NULL
)	NULL
Ab	NULL
(	NULL
1:5,000	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
detected	NULL
by	NULL
using	NULL
Attophos	NULL
Substrate	NULL
Set	NULL
(	NULL
Roche	NULL
Diagnostics	NULL
)	NULL
and	NULL
an	NULL
image	NULL
analyzer	NULL
,	NULL
the	NULL
FLA-2000	NULL
G	NULL
(	NULL
Fujifilm	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

FACS	NULL
.	NULL

Sample	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
resuspended	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
cold	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
containing	NULL
2	NULL
%	NULL
FBS	NULL
and	NULL
0.1	NULL
%	NULL
sodium	NULL
azide	NULL
(	NULL
hereinafter	NULL
called	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
[	NULL
FACS	NULL
]	NULL
buffer	NULL
)	NULL
,	NULL
preincubated	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
normal	NULL
human	NULL
IgG	NULL
solution	NULL
per	NULL
ml	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
to	NULL
block	NULL
the	NULL
crystallizable	NULL
fragment	NULL
receptor	NULL
(	NULL
FcR	NULL
)	NULL
,	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
each	NULL
fluorescence-conjugated	NULL
MAbe	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

After	NULL
being	NULL
washed	NULL
with	NULL
FACS	NULL
buffer	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
fixed	NULL
with	NULL
1	NULL
%	NULL
PFA	NULL
solution	NULL
in	NULL
PBS	NULL
and	NULL
subsequently	NULL
analyzed	NULL
on	NULL
a	NULL
FACSCali-bur	NULL
(	NULL
Becton	NULL
Dickinson	NULL
Immunocytometry	NULL
Systems	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Data	NULL
were	NULL
analyzed	NULL
using	NULL
the	NULL
CellQuest	NULL
program	NULL
(	NULL
Becton	NULL
Dickinson	NULL
Immunocytometry	NULL
Systems	NULL
)	NULL
.	NULL

Detection	NULL
of	NULL
apoptosis	NULL
.	NULL

As	NULL
described	NULL
above	NULL
,	NULL
10°	NULL
ACH-2/0X40	NULL
(	NULL
cell	NULL
groups	NULL
4	NULL
and	NULL
10	NULL
)	NULL
,	NULL
ACH-2/mock	NULL
(	NULL
cell	NULL
group	NULL
7	NULL
)	NULL
,	NULL
and	NULL
ACH-2	NULL
cells	NULL
per	NULL
well	NULL
were	NULL
stimulated	NULL
with	NULL
each	NULL
stimulus	NULL
for	NULL
5	NULL
days	NULL
.	NULL

The	NULL
numbers	NULL
of	NULL
live	NULL
cells	NULL
were	NULL
monitored	NULL
every	NULL
day	NULL
by	NULL
staining	NULL
with	NULL
trypan	NULL
blue	NULL
(	NULL
GIBCO-BRL	NULL
)	NULL
.	NULL

Morphological	NULL
changes	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
visualized	NULL
by	NULL
a	NULL
microscope	NULL
3	NULL
days	NULL
after	NULL
the	NULL
introduction	NULL
of	NULL
the	NULL
stimuli	NULL
.	NULL

DNA	NULL
fragmentation	NULL
was	NULL
then	NULL
determined	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
10°	NULL
cells	NULL
were	NULL
harvested	NULL
3	NULL
days	NULL
after	NULL
each	NULL
stimuli	NULL
,	NULL
including	NULL
anti-Fas	NULL
MAb	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
,	NULL
inducing	NULL
apoptosis	NULL
,	NULL
washed	NULL
in	NULL
cold	NULL
PBS	NULL
,	NULL
and	NULL
lysed	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
10	NULL
mM	NULL
EDTA	NULL
,	NULL
0.2	NULL
%	NULL
Triton	NULL
X-100	NULL
)	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
centrifuged	NULL
(	NULL
13,000	NULL
x	NULL
g	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
to	NULL
separate	NULL
high-molecular-weight	NULL
DNA	NULL
(	NULL
pellet	NULL
)	NULL
from	NULL
cleaved	NULL
low-molecular-weight	NULL
DNA	NULL
(	NULL
su-pernatant	NULL
)	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
incubated	NULL
with	NULL
RNase	NULL
A	NULL
(	NULL
0.2	NULL
mg/m	NULL
!	NULL
)	NULL

for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
and	NULL
then	NULL
with	NULL
proteinase	NULL
K	NULL
(	NULL
0.4	NULL
mg/m	NULL
!	NULL
)	NULL

for	NULL
2	NULL
h	NULL
at	NULL
55°C	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
extracted	NULL
with	NULL
phenol-chloroform-isoamyl	NULL
alcohol	NULL
and	NULL
then	NULL
precipitated	NULL
by	NULL
eth-anol	NULL
.	NULL

The	NULL
pellets	NULL
were	NULL
air	NULL
dried	NULL
,	NULL
resuspended	NULL
in	NULL
dissolving	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris-HCJ	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
%	NULL
SDS	NULL
)	NULL
,	NULL
and	NULL
then	NULL
incubated	NULL
at	NULL
60°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
subjected	NULL
by	NULL
electrophoresis	NULL
in	NULL
a	NULL
2	NULL
%	NULL
agarose	NULL
gel	NULL
containing	NULL
ethidium	NULL
bromide	NULL
and	NULL
then	NULL
photographed	NULL
on	NULL
an	NULL
UV	NULL
transilluminator	NULL
.	NULL

Low-molecular-weight	NULL
apoptotic	NULL
DNA	NULL
levels	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
were	NULL
also	NULL
measured	NULL
by	NULL
using	NULL
Cell	NULL
Death	NULL
Detection	NULL
ELISA	NULL
Plus	NULL
(	NULL
Roche	NULL
Diagnostics	NULL
)	NULL
.	NULL

TNF-a	NULL
and	NULL
TNF-B	NULL
assays	NULL
.	NULL

For	NULL
the	NULL
determination	NULL
of	NULL
TNF-a	NULL
and	NULL
TNF-production	NULL
,	NULL
supernatants	NULL
of	NULL
ACH-2/0X40	NULL
cells	NULL
stimulated	NULL
by	NULL
PFA-fixed	NULL
SV-T2/	NULL
gp34	NULL
cells	NULL
were	NULL
collected	NULL
at	NULL
each	NULL
time	NULL
point	NULL
(	NULL
0	NULL
,	NULL
1	NULL
,	NULL
2	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
12	NULL
,	NULL
15	NULL
,	NULL
18	NULL
,	NULL
24	NULL
,	NULL
48	NULL
,	NULL
J.	NULL
Virou	NULL
.	NULL

and	NULL
72	NULL
h	NULL
)	NULL
,	NULL
and	NULL
the	NULL
concentrations	NULL
of	NULL
TNF-a	NULL
and	NULL
TNF-	NULL
were	NULL
assayed	NULL
using	NULL
a	NULL
Quantikine	NULL
TNF-a	NULL
and	NULL
TNF-B	NULL
Kit	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
.	NULL

Luciferase	NULL
assay	NULL
.	NULL

Plasmid	NULL
DNAs	NULL
were	NULL
introduced	NULL
into	NULL
each	NULL
cell	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
DEAE-dextran	NULL
transfection	NULL
procedure	NULL
(	NULL
6	NULL
)	NULL
.	NULL

The	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
plain	NULL
RPMI	NULL
and	NULL
resuspended	NULL
in	NULL
5	NULL
ml	NULL
of	NULL
transfection	NULL
solution	NULL
(	NULL
3.35	NULL
ml	NULL
of	NULL
plain	NULL
RPMI	NULL
,	NULL
0.9	NULL
ml	NULL
of	NULL
H	NULL
,	NULL
O	NULL
,	NULL
0.25	NULL
ml	NULL
of	NULL
2	NULL
M	NULL
Tris-HCl	NULL
[	NULL
pH	NULL
7.4	NULL
]	NULL
,	NULL
0.5	NULL
ml	NULL
of	NULL
a	NULL
10-mg/ml	NULL
concentration	NULL
of	NULL
DEAE-dextran	NULL
[	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
]	NULL
containing	NULL
10	NULL
ug	NULL
of	NULL
pLTR-luc	NULL
or	NULL
pLTR-lucANF-	NULL
«	NULL
B	NULL
plus	NULL
1	NULL
ug	NULL
of	NULL
a	NULL
pRL-TK	NULL
plasmid	NULL
(	NULL
Toyo	NULL
Ink	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
as	NULL
internal	NULL
controls	NULL
.	NULL

After	NULL
incubation	NULL
at	NULL
37°C	NULL
for	NULL
30	NULL
min	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
plain	NULL
RPMI	NULL
and	NULL
then	NULL
resuspended	NULL
at	NULL
4	NULL
X	NULL
10°	NULL
cells/ml	NULL
with	NULL
RPMI-CM	NULL
,	NULL
dispensed	NULL
at	NULL
4	NULL
%	NULL
10°	NULL
cells/well	NULL
in	NULL
12-well	NULL
plates	NULL
,	NULL
and	NULL
cultured	NULL
for	NULL
40	NULL
h.	NULL
After	NULL
incubation	NULL
,	NULL
PFA-fixed	NULL
SV-T2/mock	NULL
cells	NULL
(	NULL
2:1	NULL
)	NULL
,	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
(	NULL
2:1	NULL
)	NULL
,	NULL
TNF-	NULL
«	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
,	NULL
or	NULL
medium	NULL
was	NULL
added	NULL
to	NULL
these	NULL
cells	NULL
.	NULL

The	NULL
stimulated	NULL
cells	NULL
were	NULL
harvested	NULL
after	NULL
8	NULL
h	NULL
,	NULL
and	NULL
lysed	NULL
with	NULL
40	NULL
pl	NULL
of	NULL
lysis	NULL
buffer	NULL
per	NULL
~7	NULL
X	NULL
10°	NULL
cells	NULL
.	NULL

Assays	NULL
for	NULL
luciferase	NULL
activity	NULL
were	NULL
performed	NULL
by	NULL
Dual-Luciferase	NULL
Reporter	NULL
Assay	NULL
System	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
Luminescencer	NULL
JNR	NULL
(	NULL
ATTO	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

ACH-2/0X40	NULL
cells	NULL
,	NULL
ACH-2/	NULL
mock	NULL
cells	NULL
,	NULL
and	NULL
ACH-2	NULL
cells	NULL
cocultured	NULL
with	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
(	NULL
2:1	NULL
)	NULL
or	NULL
SV-T2/mock	NULL
cells	NULL
(	NULL
2:1	NULL
)	NULL
for	NULL
3	NULL
h	NULL
or	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
TNF-	NULL
«	NULL
(	NULL
2	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
1	NULL
h	NULL
were	NULL
harvested	NULL
,	NULL
and	NULL
their	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
for	NULL
analysis	NULL
by	NULL
the	NULL
rapid	NULL
method	NULL
(	NULL
33	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
pellets	NULL
containing	NULL
5	NULL
X	NULL
10°	NULL
ACH-2/	NULL
OX40	NULL
cells	NULL
,	NULL
ACH-2/mock	NULL
cells	NULL
,	NULL
and	NULL
ACH-2	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
PBS	NULL
,	NULL
resuspended	NULL
in	NULL
400	NULL
pl	NULL
of	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
HEPES-KOH	NULL
,	NULL
pH	NULL
7.9	NULL
;	NULL
1.5	NULL
mM	NULL
MgC	NULL
]	NULL
;	NULL
;	NULL
10	NULL
mM	NULL
KCI	NULL
;	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
[	NULL
DTT	NULL
]	NULL
)	NULL
including	NULL
0.5	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
vortexed	NULL
briefly	NULL
,	NULL
and	NULL
microcentrifuged	NULL
at	NULL
13,000	NULL
x	NULL
g	NULL
for	NULL
10	NULL
s	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
removed	NULL
,	NULL
and	NULL
the	NULL
nuclear	NULL
pellets	NULL
were	NULL
suspended	NULL
in	NULL
20	NULL
pl	NULL
of	NULL
buffer	NULL
C	NULL
(	NULL
20	NULL
mM	NULL
HEPES-KOH	NULL
,	NULL
pH	NULL
7.9	NULL
;	NULL
2.5	NULL
%	NULL
glycerol	NULL
;	NULL
420	NULL
mM	NULL
NaCl	NULL
;	NULL
1.5	NULL
mM	NULL
MgC	NULL
)	NULL
;	NULL
0.2	NULL
mM	NULL
EDTA	NULL
;	NULL
0.5	NULL
mM	NULL
DTT	NULL
;	NULL
0.5	NULL
mM	NULL
PMSF	NULL
)	NULL
,	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
vortexed	NULL
briefly	NULL
,	NULL
and	NULL
microcentrifuged	NULL
at	NULL
13,000	NULL
x	NULL
g	NULL
for	NULL
2	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
collected	NULL
,	NULL
the	NULL
protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Bradford	NULL
(	NULL
5	NULL
)	NULL
,	NULL
and	NULL
the	NULL
supernatants	NULL
were	NULL
stored	NULL
at	NULL
-80°C	NULL
before	NULL
use	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
oligonucleotides	NULL
used	NULL
for	NULL
the	NULL
probes	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
wild-type	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
5'-AATTCAAGGGACTTTCCGCTG	NULL
GGGACTTTICCAG	NULL
and	NULL
GTTCCCTGAAAGGCGACCCCTGAAAGGTCCTAG-5	NULL
;	NULL
and	NULL
mutant	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
5'-AATTCAACTCACTTTCCGCTGCTCACTTTC	NULL
CAG	NULL
and	NULL
GTTGAGTGAAAGGCGACGAGTGAAAGGTCCTAG-5	NULL
'	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
binding	NULL
sequence	NULL
is	NULL
shown	NULL
in	NULL
boldface	NULL
type	NULL
,	NULL
and	NULL
the	NULL
mutated	NULL
sites	NULL
are	NULL
italicized	NULL
.	NULL

Each	NULL
oligonucleotide	NULL
was	NULL
annealed	NULL
to	NULL
its	NULL
complementary	NULL
strand	NULL
and	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
y-	NULL
>	NULL
°P	NULL
]	NULL
JATP	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
using	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
TaKaRa	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

0.2	NULL
pmol	NULL
of	NULL
y-	NULL
``	NULL
°P-labeled	NULL
double-stranded	NULL
probe	NULL
(	NULL
~30,000	NULL
cpm	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
and	NULL
1	NULL
pg	NULL
of	NULL
poly	NULL
{	NULL
d	NULL
(	NULL
I-C	NULL
)	NULL
]	NULL
(	NULL
Roche	NULL
Diagnostics	NULL
)	NULL
in	NULL
20	NULL
pl	NULL
of	NULL
buffer	NULL
D	NULL
(	NULL
20	NULL
mM	NULL
HEPES-KOH	NULL
,	NULL
pH	NULL
7.9	NULL
;	NULL
2.5	NULL
%	NULL
glycerol	NULL
;	NULL
100	NULL
mM	NULL
KCI	NULL
;	NULL
0.2	NULL
mM	NULL
EDTA	NULL
;	NULL
0.5	NULL
mM	NULL
DTT	NULL
;	NULL
0.5	NULL
mM	NULL
PMSF	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Specific	NULL
binding	NULL
was	NULL
controlled	NULL
by	NULL
competition	NULL
with	NULL
a	NULL
50-fold	NULL
excess	NULL
(	NULL
10	NULL
pmol	NULL
)	NULL
of	NULL
the	NULL
wild-type	NULL
or	NULL
mutant	NULL
nonradioactive	NULL
oligonucleotide	NULL
,	NULL
incubated	NULL
with	NULL
the	NULL
nuclear	NULL
extract	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
before	NULL
the	NULL
binding	NULL
reaction	NULL
was	NULL
started	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
subunits	NULL
constituting	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
,	NULL
specific	NULL
Abs	NULL
against	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
,	NULL
c-Rel	NULL
,	NULL
and	NULL
Rel-B	NULL
were	NULL
used	NULL
.	NULL

Abs	NULL
were	NULL
added	NULL
to	NULL
the	NULL
nuclear	NULL
extract	NULL
,	NULL
and	NULL
the	NULL
mixture	NULL
was	NULL
allowed	NULL
to	NULL
stand	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
before	NULL
incubation	NULL
with	NULL
the	NULL
radiolabeled	NULL
probe	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
in	NULL
5	NULL
%	NULL
(	NULL
29:1	NULL
)	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
%	NULL
TBE	NULL
(	NULL
44.5	NULL
mM	NULL
Tris	NULL
,	NULL
44.5	NULL
mM	NULL
boric	NULL
acid	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
)	NULL
.	NULL

After	NULL
electrophoresis	NULL
,	NULL
the	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
autoradiographed	NULL
.	NULL

RESULTS	NULL
Triggering	NULL
of	NULL
OX40	NULL
by	NULL
gp34	NULL
stimulates	NULL
HIV-1	NULL
production	NULL
from	NULL
chronically	NULL
infected	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
potential	NULL
role	NULL
of	NULL
interaction	NULL
between	NULL
gp34	NULL
and	NULL
OX40	NULL
in	NULL
HIV	NULL
replication	NULL
,	NULL
we	NULL
used	NULL
chronically	NULL
HIV-1-infected	NULL
T-cell	NULL
lines	NULL
,	NULL
ACH-2	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
OX40	NULL
and	NULL
gp34	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
was	NULL
examined	NULL
by	NULL
FACS	NULL
analysis	NULL
.	NULL

The	NULL
ACH-2	NULL
cells	NULL
did	NULL
not	NULL
express	NULL
gp34	NULL
and	NULL
OX40	NULL
on	NULL
their	NULL
surfaces	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
established	NULL
stable	NULL
human	NULL
OX4O0-expressing	NULL
ACH-2	NULL
,	NULL
ACH-2/	NULL
OX40	NULL
cells	NULL
,	NULL
and	NULL
ACH-2/mock	NULL
cells	NULL
by	NULL
electroporation	NULL
of	NULL
the	NULL
pCAGIPuro/OX40	NULL
vector	NULL
and	NULL
the	NULL
pCAGIPuro	NULL
vector	NULL
alone	NULL
without	NULL
an	NULL
insert	NULL
as	NULL
a	NULL
control	NULL
,	NULL
respectively	NULL
.	NULL

As	NULL
a	NULL
stimulator	NULL
,	NULL
we	NULL
also	NULL
established	NULL
gp34-transfected	NULL
mouse	NULL
cell	NULL
line	NULL
SV-T2	NULL
,	NULL
SV-T2/gp34	NULL
cells	NULL
and	NULL
empty	NULL
vector-transfected	NULL
SV-T2	NULL
,	NULL
SV-T2/	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
A.	NULL
p24	NULL
concentration	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

ACH-2/0X40	NULL
107	NULL
L	NULL
]	NULL
+	NULL
SV-T2/mock	NULL
IN	NULL
+	NULL
SV-T2/gp34	NULL
p24	NULL
concentration	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

Un	NULL
1	NULL
WU	NULL
)	NULL
i	NULL
so	NULL
ON-	NULL
10	NULL
s	NULL
A-	NULL
i	NULL
£Cco	NULL
8I—__I_J	NULL
2	NULL
GG	NULL
R	NULL
+Cont	NULL
.	NULL

+	NULL
5A8	NULL
+	NULL
+	NULL
+o	NULL
0+	NULL
(	NULL
ug/m	NULL
!	NULL

t	NULL
)	NULL
ENHANCED	NULL
HIV-1	NULL
PRODUCTION	NULL
BY	NULL
OX40	NULL
COSTIMULATION	NULL
6751	NULL
FA	NULL
+	NULL
Medium	NULL
[	NULL
]	NULL
+SV-T2/mock	NULL
BN	NULL
+	NULL
SV-T2/gp34	NULL
N	NULL
+	NULL
TNF-a	NULL
+	NULL
TNF-B	NULL
oo	NULL
#	NULL
s	NULL
_	NULL
#	NULL
40	NULL
ACH	NULL
-2/mock	NULL
30	NULL
--	NULL
O-	NULL
+	NULL
Medium	NULL
-O-	NULL
+	NULL
SV-T2/mock	NULL
-B-	NULL
+	NULL
SV-T2/gp34	NULL
+	NULL
TNF-a	NULL
207	NULL
107	NULL
p24	NULL
concentration	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

04	NULL
Days	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Enhanced	NULL
expression	NULL
of	NULL
HIV-1	NULL
by	NULL
OX40	NULL
stimulation	NULL
from	NULL
HIV-1	NULL
chronically	NULL
infected	NULL
ACH-2/0X40	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Five	NULL
groups	NULL
of	NULL
ACH-2/0X40	NULL
cells	NULL
(	NULL
cell	NULL
groups	NULL
3	NULL
,	NULL
4	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
10	NULL
)	NULL
,	NULL
four	NULL
groups	NULL
ACH-2/mock	NULL
cells	NULL
(	NULL
cell	NULL
groups	NULL
2	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
,	NULL
and	NULL
the	NULL
parental	NULL
ACH-2	NULL
cell	NULL
line	NULL
were	NULL
stimulated	NULL
by	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
or	NULL
PFA-fixed	NULL
SV-T2/mock	NULL
cells	NULL
at	NULL
a	NULL
cell	NULL
ratio	NULL
of	NULL
2:1	NULL
with	NULL
TNF-	NULL
«	NULL
(	NULL
2	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
TNF-B	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
.	NULL

After	NULL
3	NULL
days	NULL
,	NULL
HIV-1	NULL
production	NULL
was	NULL
determined	NULL
quantitatively	NULL
by	NULL
p24	NULL
assay	NULL
using	NULL
the	NULL
culture	NULL
supernatants	NULL
.	NULL

(	NULL
B	NULL
)	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
and	NULL
PFA-fixed	NULL
SV-T2/mock	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
or	NULL
without	NULL
anti-gp34	NULL
neutralizing	NULL
MAb	NULL
(	NULL
5A8	NULL
)	NULL
or	NULL
control	NULL
MAb	NULL
(	NULL
Cont	NULL
.	NULL
)	NULL

at	NULL
5	NULL
,	NULL
1	NULL
,	NULL
0.2	NULL
,	NULL
or	NULL
0.04	NULL
g/ml	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
and	NULL
then	NULL
were	NULL
added	NULL
to	NULL
ACH-2/0X40	NULL
cells	NULL
.	NULL

Culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
3	NULL
days	NULL
after	NULL
coculture	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Kinetics	NULL
of	NULL
HIV-1	NULL
expression	NULL
after	NULL
stimulation	NULL
with	NULL
gp34	NULL
in	NULL
ACH-2/0X40	NULL
cells	NULL
.	NULL

Supernatants	NULL
were	NULL
harvested	NULL
at	NULL
each	NULL
time	NULL
point	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
at	NULL
0	NULL
,	NULL
2	NULL
,	NULL
4	NULL
,	NULL
8	NULL
,	NULL
12	NULL
,	NULL
18	NULL
,	NULL
24	NULL
,	NULL
48	NULL
,	NULL
72	NULL
,	NULL
96	NULL
,	NULL
and	NULL
120	NULL
h	NULL
,	NULL
and	NULL
then	NULL
tested	NULL
for	NULL
p24	NULL
titers	NULL
.	NULL

All	NULL
results	NULL
are	NULL
the	NULL
means	NULL
of	NULL
values	NULL
obtained	NULL
in	NULL
triplicate	NULL
.	NULL

A	NULL
representative	NULL
result	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

mock	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
all	NULL
the	NULL
ACH-2/0X40	NULL
cells	NULL
(	NULL
cell	NULL
groups	NULL
3	NULL
,	NULL
4	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
10	NULL
)	NULL
tested	NULL
were	NULL
apparently	NULL
enhanced	NULL
for	NULL
HIV-1	NULL
expression	NULL
through	NULL
signaling	NULL
from	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
control	NULL
coculture	NULL
with	NULL
OX40~	NULL
ACH-2/	NULL
mock	NULL
cells	NULL
(	NULL
cell	NULL
groups	NULL
2	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
or	NULL
ACH-2	NULL
cell	NULL
lines	NULL
,	NULL
the	NULL
production	NULL
of	NULL
HIV-1	NULL
remained	NULL
at	NULL
the	NULL
basal	NULL
level	NULL
.	NULL

Importantly	NULL
,	NULL
enhanced	NULL
expression	NULL
of	NULL
HIV-1	NULL
from	NULL
ACH-2/0X40	NULL
#	NULL
10	NULL
cells	NULL
by	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
was	NULL
dose	NULL
dependently	NULL
inhibited	NULL
by	NULL
the	NULL
anti-gp34	NULL
MAb	NULL
5A8	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
kinetic	NULL
studies	NULL
showed	NULL
that	NULL
HIV-1	NULL
expression	NULL
by	NULL
interaction	NULL
of	NULL
gp34	NULL
and	NULL
OX40	NULL
could	NULL
be	NULL
detected	NULL
as	NULL
early	NULL
as	NULL
18	NULL
h	NULL
after	NULL
cocultivation	NULL
and	NULL
that	NULL
HIV-1	NULL
p24	NULL
increased	NULL
over	NULL
time	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
also	NULL
obtained	NULL
in	NULL
another	NULL
cells	NULL
,	NULL
ACH-2/0X40	NULL
#	NULL
4	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
clearly	NULL
showed	NULL
that	NULL
triggering	NULL
of	NULL
OX4O0	NULL
by	NULL
its	NULL
ligand	NULL
,	NULL
gp34/OX4A0L	NULL
,	NULL
stimulates	NULL
HIV-1	NULL
production	NULL
from	NULL
T	NULL
cells	NULL
persistently	NULL
infected	NULL
with	NULL
HIV-1	NULL
.	NULL

Triggering	NULL
of	NULL
OX40	NULL
by	NULL
gp34	NULL
induces	NULL
apoptosis	NULL
in	NULL
chronically	NULL
infected	NULL
T	NULL
cells	NULL
.	NULL

Since	NULL
the	NULL
gp34/OX40	NULL
system	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
modulation	NULL
of	NULL
proliferation	NULL
in	NULL
different	NULL
cellular	NULL
systems	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
HIV-1	NULL
induction	NULL
by	NULL
67532	NULL
TAKAHASHI	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

A.	NULL
C.	NULL
ACH-2/0	NULL
%	NULL
40	NULL
ACH-2/mock	NULL
ACH	NULL
200	NULL
I	NULL
-o-	NULL
+	NULL
Medium	NULL
5	NULL
3	NULL
&	NULL
-a-	NULL
+	NULL
SV-Tamock	NULL
£	NULL
§	NULL
a	NULL
200	NULL
R	NULL
-m-	NULL
+	NULL
§	NULL
3	NULL
a	NULL
f	NULL
=	NULL
$	NULL
5	NULL
*	NULL
.3	NULL
-	NULL
p-	NULL
LE	NULL
I	NULL
LL	NULL
.	NULL

_	NULL
-e-	NULL
+	NULL
TNF-a	NULL
3	NULL
$	NULL
'	NULL
br	NULL
0	NULL
°	NULL
>	NULL
>	NULL
Z	NULL
Z	NULL
C	NULL
g	NULL
-a-	NULL
+	NULL
TNF-B	NULL
=	NULL
&	NULL
&	NULL
A	NULL
EF	NULL
if	NULL
<	NULL
5	NULL
100	NULL
1	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
8	NULL
$	NULL
S	NULL
>	NULL
@	NULL
cl	NULL
-	NULL
(	NULL
J	NULL
Jo	NULL
.	NULL

ccl..	NULL
Prion	NULL
00	NULL
4	NULL
o	NULL
2	NULL
o	NULL
:	NULL
4	NULL
5	NULL
10	NULL
g	NULL
og	NULL
405	NULL
Days	NULL
B.	NULL
ACH-2/0	NULL
%	NULL
40	NULL
ACH-2/mock	NULL
+	NULL
Medium	NULL
D.	NULL
ACH-2/0	NULL
%	NULL
40	NULL
2-+	NULL
SV-T2/mock	NULL
&	NULL
o	NULL
C	NULL
G	NULL
8	NULL
a-+	NULL
SV-T2/2gp34	NULL
9	NULL
A	NULL
<	NULL
¥	NULL
a	NULL
4	NULL
%	NULL
ge	NULL
At	NULL
«	NULL
3	NULL
55A	NULL
+	NULL
TNF-a	NULL
x	NULL
<	NULL
$	NULL
%	NULL
tx	NULL
0	NULL
-	NULL
F	NULL
%	NULL
*	NULL
,	NULL
x2	NULL
``	NULL
®	NULL
€	NULL
6	NULL
<	NULL
C	NULL
z	NULL
A	NULL
3	NULL
0	NULL
2	NULL
0	NULL
u	NULL
w	NULL
u	NULL
3	NULL
OE	NULL
S	NULL
2	NULL
2	NULL
:	NULL
Cd	NULL
&	NULL
&	NULL
a	NULL
*	NULL
ma	NULL
*	NULL
*	NULL
I	NULL
E	NULL
E	NULL
,	NULL
P.-	NULL
*	NULL
*	NULL
<	NULL
d	NULL
_r	NULL
‘	NULL
A	NULL
‘	NULL
.-§	NULL
his	NULL
'	NULL
£	NULL
w	NULL
a	NULL
)	NULL
5	NULL
)	NULL
*	NULL
'*	NULL
'	NULL
g	NULL
w	NULL
B	NULL
Va	NULL
L*	NULL
A	NULL
4	NULL
If	NULL
it	NULL
“	NULL
.	NULL

+	NULL
ﬁat	NULL
}	NULL
;	NULL
41:1	NULL
;	NULL
C	NULL
+0	NULL
+	NULL
TNF-B	NULL
*	NULL
*	NULL
+ee	NULL
39	NULL
*	NULL
-¥	NULL
,	NULL
a	NULL
I	NULL
~	NULL
a	NULL
``	NULL
ii	NULL
!	NULL

FIG	NULL
.	NULL

2	NULL
.	NULL

Detection	NULL
of	NULL
apoptosis	NULL
of	NULL
the	NULL
ACH-2/0X40	NULL
cells	NULL
stimulated	NULL
with	NULL
gp34	NULL
.	NULL

(	NULL
A	NULL
)	NULL
ACH-2/0X40	NULL
#	NULL
10	NULL
cells	NULL
and	NULL
ACH-2/mock	NULL
#	NULL
7	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
5	NULL
days	NULL
with	NULL
medium	NULL
alone	NULL
,	NULL
PFA-fixed	NULL
SV-T2/mock	NULL
cells	NULL
,	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
,	NULL
TNF-	NULL
«	NULL
,	NULL
or	NULL
TNF-B	NULL
and	NULL
then	NULL
examined	NULL
for	NULL
viable	NULL
cell	NULL
number	NULL
under	NULL
a	NULL
microscope	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
numbers	NULL
of	NULL
living	NULL
cells	NULL
obtained	NULL
in	NULL
triplicate	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Morphological	NULL
alteration	NULL
of	NULL
ACH-20X40	NULL
#	NULL
10	NULL
cells	NULL
and	NULL
ACH-2/mock	NULL
#	NULL
7	NULL
cells	NULL
3	NULL
days	NULL
after	NULL
the	NULL
introduction	NULL
of	NULL
various	NULL
stimuli	NULL
.	NULL

Original	NULL
magnification	NULL
,	NULL
X200	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Nuclear	NULL
DNA	NULL
fragmentation	NULL
of	NULL
ACH-2/0X40	NULL
#	NULL
10	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
by	NULL
apoptosis	NULL
was	NULL
analyzed	NULL
by	NULL
2	NULL
%	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
3	NULL
days	NULL
after	NULL
the	NULL
stimuli	NULL
.	NULL

Anti-Fas	NULL
MAb	NULL
(	NULL
CH-11	NULL
)	NULL
was	NULL
used	NULL
as	NULL
positive	NULL
control	NULL
.	NULL

(	NULL
D	NULL
)	NULL
The	NULL
apoptotic	NULL
DNAs	NULL
of	NULL
ACH-2/0X40	NULL
#	NULL
10	NULL
cells	NULL
(	NULL
10°/Awell	NULL
)	NULL
were	NULL
measured	NULL
by	NULL
using	NULL
an	NULL
ELISA	NULL
kit	NULL
3	NULL
days	NULL
after	NULL
various	NULL
stimuli	NULL
.	NULL

The	NULL
results	NULL
are	NULL
a	NULL
mean	NULL
number	NULL
of	NULL
absorbance	NULL
values	NULL
obtained	NULL
in	NULL
triplicate	NULL
.	NULL

Representative	NULL
results	NULL
are	NULL
shown	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

coculture	NULL
was	NULL
associated	NULL
with	NULL
an	NULL
effect	NULL
on	NULL
the	NULL
proliferation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Interestingly	NULL
,	NULL
when	NULL
cells	NULL
of	NULL
the	NULL
ACH-2/	NULL
OX40	NULL
#	NULL
10	NULL
cells	NULL
were	NULL
induced	NULL
for	NULL
HIV-1	NULL
production	NULL
by	NULL
gp34	NULL
,	NULL
they	NULL
apparently	NULL
underwent	NULL
cell	NULL
growth	NULL
retardation	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
and	NULL
morphological	NULL
change	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
viability	NULL
was	NULL
only	NULL
about	NULL
40	NULL
%	NULL
2	NULL
days	NULL
after	NULL
coculture	NULL
and	NULL
,	NULL
after	NULL
that	NULL
,	NULL
surviving	NULL
cells	NULL
recovered	NULL
and	NULL
increased	NULL
gradually	NULL
in	NULL
numbers	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
cell	NULL
growth	NULL
and	NULL
morphology	NULL
was	NULL
similar	NULL
to	NULL
the	NULL
effect	NULL
of	NULL
TNF-a	NULL
.	NULL

TNF-	NULL
«	NULL
treatment	NULL
of	NULL
ACH-2/0X40	NULL
cells	NULL
resulted	NULL
in	NULL
much	NULL
stronger	NULL
cell	NULL
killing	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
TNF-B	NULL
induced	NULL
a	NULL
little	NULL
cell	NULL
death	NULL
in	NULL
each	NULL
cell	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
demonstrated	NULL
by	NULL
electrophoresis	NULL
on	NULL
an	NULL
agarose	NULL
gel	NULL
of	NULL
the	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
and	NULL
with	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
30	NULL
H	NULL
+	NULL
PBS	NULL
[	NULL
]	NULL
+	NULL
Control	NULL
IgG1	NULL
+	NULL
Anti-TNF-a	NULL
op-	NULL
B	NULL
+	NULL
107	NULL
p24	NULL
concentration	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

0-4	NULL
J	NULL
C____	NULL
900-71	NULL
I	NULL
i	NULL
+Medium	NULL
+SV-T2/	NULL
+SV-T2/	NULL
+TNF-a	NULL
+TNF-B	NULL
mock	NULL
_	NULL
gp34	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Autocrine	NULL
secretion	NULL
of	NULL
TNF-	NULL
«	NULL
and	NULL
TNF-B	NULL
does	NULL
not	NULL
account	NULL
for	NULL
enhanced	NULL
HIV-1	NULL
expression	NULL
in	NULL
ACH-2/0X40	NULL
cells	NULL
stimulated	NULL
with	NULL
gp34	NULL
.	NULL

ACH-2/0X40	NULL
#	NULL
10	NULL
cells	NULL
were	NULL
cocultured	NULL
with	NULL
PFA-fixed	NULL
SV-T2/	NULL
gp34	NULL
cells	NULL
or	NULL
PFA-fixed	NULL
SV-T2/mock	NULL
cells	NULL
at	NULL
a	NULL
cell	NULL
ratio	NULL
of	NULL
2:1	NULL
or	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TNF-	NULL
«	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
or	NULL
TNF-	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

after	NULL
preincubation	NULL
with	NULL
or	NULL
without	NULL
anti-human	NULL
TNF-	NULL
«	NULL
neutralizing	NULL
MAb	NULL
(	NULL
50	NULL
pg/m	NULL
!	NULL
)	NULL

,	NULL
anti-human	NULL
TNF-	NULL
neutralizing	NULL
MAb	NULL
(	NULL
5	NULL
g/ml	NULL
)	NULL
,	NULL
or	NULL
control	NULL
MAb	NULL
(	NULL
50	NULL
pg/ml	NULL
!	NULL
)	NULL

for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
after	NULL
3	NULL
days	NULL
,	NULL
and	NULL
then	NULL
the	NULL
HIV-1	NULL
p24	NULL
level	NULL
was	NULL
measured	NULL
.	NULL

The	NULL
results	NULL
are	NULL
the	NULL
means	NULL
of	NULL
values	NULL
obtained	NULL
in	NULL
triplicate	NULL
.	NULL

Representative	NULL
results	NULL
are	NULL
shown	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

the	NULL
use	NULL
of	NULL
an	NULL
ELISA	NULL
kit	NULL
that	NULL
measures	NULL
the	NULL
presence	NULL
of	NULL
histone-associated	NULL
DNA	NULL
fragments	NULL
(	NULL
Fig	NULL
.	NULL

2D	NULL
)	NULL
that	NULL
this	NULL
cell	NULL
death	NULL
was	NULL
due	NULL
to	NULL
apoptosis	NULL
.	NULL

Very	NULL
similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
another	NULL
ACH-2/0X40	NULL
#	NULL
4	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
ACH-2/mock	NULL
#	NULL
7	NULL
cells	NULL
and	NULL
the	NULL
parental	NULL
ACH-2	NULL
cell	NULL
line	NULL
,	NULL
apoptosis	NULL
was	NULL
induced	NULL
by	NULL
TNF-a	NULL
but	NULL
was	NULL
not	NULL
induced	NULL
by	NULL
gp34	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

HIV	NULL
expression	NULL
by	NULL
triggered	NULL
OX40	NULL
is	NULL
not	NULL
mediated	NULL
by	NULL
endogenous	NULL
TNF	NULL
secretion	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
autocrine	NULL
secretion	NULL
of	NULL
TNF	NULL
was	NULL
responsible	NULL
for	NULL
HIV-1	NULL
expression	NULL
caused	NULL
by	NULL
OX40-stimulation	NULL
.	NULL

Figure	NULL
3	NULL
shows	NULL
that	NULL
blocking	NULL
Abs	NULL
directed	NULL
against	NULL
TNF-a	NULL
and	NULL
TNF-	NULL
abrogated	NULL
HIV	NULL
production	NULL
from	NULL
ACH-2/	NULL
OX40	NULL
#	NULL
10	NULL
cells	NULL
induced	NULL
by	NULL
the	NULL
respective	NULL
cytokines	NULL
,	NULL
but	NULL
these	NULL
two	NULL
Abs	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
HIV-1	NULL
expression	NULL
enhanced	NULL
by	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
interaction	NULL
of	NULL
gp34	NULL
and	NULL
OX40	NULL
on	NULL
ACH-2/0X40	NULL
cells	NULL
leads	NULL
to	NULL
enhanced	NULL
virus	NULL
production	NULL
independent	NULL
of	NULL
endogenous	NULL
secretion	NULL
of	NULL
TNF-	NULL
«	NULL
or	NULL
TNF-B	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
level	NULL
of	NULL
TNF-	NULL
«	NULL
and	NULL
TNF-B	NULL
in	NULL
the	NULL
supernatants	NULL
from	NULL
ACH-2/0X40	NULL
#	NULL
10	NULL
cells	NULL
cocultivated	NULL
with	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
was	NULL
<	NULL
10	NULL
pg/ml	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
also	NULL
obtained	NULL
in	NULL
another	NULL
cells	NULL
,	NULL
ACH-2/	NULL
OX40	NULL
#	NULL
4	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

B	NULL
sites	NULL
in	NULL
the	NULL
LTR	NULL
are	NULL
required	NULL
for	NULL
HIV	NULL
transcription	NULL
induced	NULL
by	NULL
interaction	NULL
of	NULL
gp34	NULL
and	NULL
OX40	NULL
.	NULL

Because	NULL
it	NULL
has	NULL
been	NULL
described	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
HIV-1	NULL
transcription	NULL
by	NULL
TNF-	NULL
«	NULL
in	NULL
ACH-2	NULL
cells	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
the	NULL
same	NULL
was	NULL
true	NULL
for	NULL
HIV-1	NULL
expression	NULL
by	NULL
OXA40-stimulation	NULL
.	NULL

ACH-2/0X40	NULL
#	NULL
4	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
either	NULL
with	NULL
an	NULL
HIV	NULL
LTR	NULL
construct	NULL
linked	NULL
to	NULL
the	NULL
reporter	NULL
gene	NULL
luciferase	NULL
(	NULL
pLTR-luc	NULL
)	NULL
or	NULL
with	NULL
its	NULL
respective	NULL
plasmid	NULL
in	NULL
which	NULL
the	NULL
xB	NULL
sites	NULL
were	NULL
deleted	NULL
(	NULL
pLTR-lucANF-B	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
OX40	NULL
by	NULL
coculture	NULL
with	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
ENHANCED	NULL
HIV-1	NULL
PRODUCTION	NULL
BY	NULL
OX40	NULL
COSTIMULATION	NULL
_	NULL
6753	NULL
507	NULL
B	NULL
2	NULL
J	NULL
]	NULL
AkB-lue	NULL
2	NULL
40-7	NULL
o	NULL
G	NULL
O	NULL
#	NULL
©	NULL
-	NULL
307	NULL
&	NULL
'	NULL
O	NULL
3	NULL
I	NULL
20	NULL
.N	NULL
C	NULL
*	NULL
10-l_\	NULL
~	NULL
I_	NULL
‘	NULL
OJL	NULL
1	NULL
I	NULL
J	NULL
I	NULL
+	NULL
Medium	NULL
+SV-T2/	NULL
+SV-T2/	NULL
mock	NULL
gp34	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Transcriptional	NULL
activity	NULL
of	NULL
HIV	NULL
LTR	NULL
induced	NULL
by	NULL
OX40	NULL
stimulation	NULL
.	NULL

ACH-2/0X40	NULL
#	NULL
4	NULL
cells	NULL
were	NULL
cotransfected	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
transfection	NULL
procedure	NULL
with	NULL
the	NULL
constructs	NULL
of	NULL
wild-type	NULL
pLTR-lue	NULL
(	NULL
WT-luc	NULL
)	NULL
or	NULL
«	NULL
B-deleted	NULL
type	NULL
pLTR-lucANF-kB	NULL
(	NULL
AkB-lue	NULL
)	NULL
(	NULL
101g/	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
)	NULL
,	NULL
and	NULL
pRL-TK	NULL
(	NULL
1	NULL
pg/5	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
.	NULL

The	NULL
transfectants	NULL
were	NULL
cultured	NULL
for	NULL
40	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Luciferase	NULL
activities	NULL
were	NULL
determined	NULL
8	NULL
h	NULL
after	NULL
stimulation	NULL
by	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
or	NULL
PFA-fixed	NULL
SV-T2/mock	NULL
cells	NULL
at	NULL
a	NULL
cell	NULL
ratio	NULL
of	NULL
2:1	NULL
,	NULL
by	NULL
TNF-a	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
,	NULL
or	NULL
with	NULL
medium	NULL
alone	NULL
.	NULL

Transcriptional	NULL
activity	NULL
of	NULL
HIV	NULL
LTR	NULL
was	NULL
expressed	NULL
as	NULL
normalized	NULL
luciferase	NULL
activity	NULL
.	NULL

The	NULL
results	NULL
are	NULL
the	NULL
means	NULL
of	NULL
values	NULL
obtained	NULL
in	NULL
triplicate	NULL
.	NULL

Three	NULL
independent	NULL
experiments	NULL
showed	NULL
similar	NULL
results	NULL
.	NULL

+	NULL
TNF-a	NULL
cells	NULL
resulted	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
luciferase	NULL
activity	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
pLTR-Luc	NULL
wild-type	NULL
construct	NULL
(	NULL
ca	NULL
.	NULL

fourfold	NULL
higher	NULL
than	NULL
baseline	NULL
;	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
but	NULL
not	NULL
with	NULL
the	NULL
deleted	NULL
kB	NULL
construct	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
also	NULL
obtained	NULL
in	NULL
another	NULL
cells	NULL
,	NULL
ACH-2/0X40	NULL
#	NULL
10	NULL
(	NULL
approximately	NULL
twofold	NULL
higher	NULL
than	NULL
baseline	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
the	NULL
ACH-2/mock	NULL
#	NULL
7	NULL
cells	NULL
and	NULL
ACH-2	NULL
cell	NULL
line	NULL
,	NULL
HIV-1	NULL
LTR	NULL
transactivations	NULL
were	NULL
induced	NULL
by	NULL
TNF-	NULL
«	NULL
,	NULL
but	NULL
they	NULL
remained	NULL
at	NULL
the	NULL
basal	NULL
level	NULL
with	NULL
gp34	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
clearly	NULL
indicate	NULL
that	NULL
trans-activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
by	NULL
OX40	NULL
cross-linking	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
NF-kB	NULL
sequences	NULL
in	NULL
the	NULL
LTR	NULL
.	NULL

Interaction	NULL
of	NULL
gp34	NULL
and	NULL
OX40	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
NF-KB	NULL
in	NULL
ACH-2/0X40	NULL
cells	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
OX40	NULL
stimulation	NULL
by	NULL
gp34	NULL
induces	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
in	NULL
ACH-2/0X40	NULL
cells	NULL
,	NULL
we	NULL
performed	NULL
EMSA	NULL
.	NULL

ACH-2/0X40	NULL
#	NULL
10	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
or	NULL
without	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
,	NULL
PFA-fixed	NULL
SV-T2/mock	NULL
cells	NULL
,	NULL
or	NULL
TNF-	NULL
«	NULL
,	NULL
and	NULL
then	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
after	NULL
3	NULL
h	NULL
(	NULL
in	NULL
the	NULL
case	NULL
of	NULL
cocultivation	NULL
with	NULL
SV-T2/gp34	NULL
cells	NULL
or	NULL
SV-T2/mock	NULL
cells	NULL
)	NULL
or	NULL
1	NULL
h	NULL
(	NULL
for	NULL
TNF-	NULL
«	NULL
or	NULL
medium	NULL
alone	NULL
)	NULL
;	NULL
nuclear	NULL
extracts	NULL
were	NULL
then	NULL
prepared	NULL
.	NULL

The	NULL
bands	NULL
,	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
of	NULL
gp34-stimulated	NULL
ACH-2/0X40	NULL
cells	NULL
were	NULL
NF-kB	NULL
specific	NULL
since	NULL
they	NULL
are	NULL
apparently	NULL
abrogated	NULL
with	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
cold	NULL
NF-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
but	NULL
not	NULL
with	NULL
a	NULL
mutated	NULL
NF-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
8	NULL
to	NULL
10	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
is	NULL
comprised	NULL
of	NULL
several	NULL
molecules	NULL
that	NULL
can	NULL
dimerize	NULL
and	NULL
thus	NULL
result	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
different	NULL
complexes	NULL
,	NULL
we	NULL
further	NULL
investigated	NULL
which	NULL
molecules	NULL
were	NULL
involved	NULL
in	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
specific	NULL
bands	NULL
of	NULL
gp34-stimulated	NULL
ACH-2/0X40	NULL
cells	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
supershift	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
nuclear	NULL
extracts	NULL
of	NULL
gp34	NULL
67534	NULL
TAKAHASHI	NULL
ET	NULL
AL	NULL
.	NULL

A.	NULL
ACH-2/0X40	NULL
Nuclear	NULL
extracts	NULL
O	NULL
oor	NULL
1	NULL
+	NULL
Medium	NULL
-	NULL
+	NULL
SV-Ta/mock	NULL
+	NULL
SV-T2igp34	NULL
_	NULL
+	NULL
TNF-a	NULL
FI	NULL
1	NULL
of	NULL
1	NULL
of	NULL
10	NULL
1	NULL
a	NULL
a	NULL
a	NULL
a	NULL
x	NULL
5	NULL
Fi	NULL
*	NULL
u	NULL
U	NULL
U	NULL
u	NULL
Competitors	NULL
2	NULL
2	NULL
Z	NULL
2	NULL
s	NULL
§	NULL
g	NULL
$	NULL
o	NULL
s	NULL
$	NULL
o	NULL
2	NULL
P	NULL
S	NULL
.	NULL

z	NULL
as	NULL
&	NULL
fos	NULL
&	NULL
fog	NULL
}	NULL
fo	NULL
c	NULL
%	NULL
f	NULL
-	NULL
<	NULL
-Lanes	NULL
B.	NULL
ACH-2/0X40	NULL
Nuclear	NULL
extracts	NULL
4	NULL
+	NULL
SV-T2igp34	NULL
+	NULL
TNF-a	NULL
U	NULL
[	NULL
C	NULL
]	NULL
1	NULL
J	NULL
U	NULL
3	NULL
$	NULL
€	NULL
s	NULL
©	NULL
€	NULL
a	NULL
Antibodies	NULL
€	NULL
€	NULL
c	NULL
&	NULL
w	NULL
o	NULL
in	NULL
a	NULL
8	NULL
5	NULL
:	NULL
ae	NULL
$	NULL
f	NULL
$	NULL
5	NULL
:	NULL
ae	NULL
f	NULL
:	NULL
AA	NULL
hl	NULL
«	NULL
me	NULL
3	NULL
I	NULL
Lanes	NULL
1	NULL
20	NULL
3	NULL
4	NULL
§	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
induced	NULL
by	NULL
cross-linking	NULL
of	NULL
OX40	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Analysis	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
by	NULL
EMSA	NULL
.	NULL

ACH-2/0X40	NULL
#	NULL
10	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
or	NULL
PFA-fixed	NULL
SV-T2/mock	NULL
cells	NULL
at	NULL
a	NULL
cell	NULL
ratio	NULL
of	NULL
2:1	NULL
or	NULL
were	NULL
cultured	NULL
for	NULL
1	NULL
h	NULL
with	NULL
TNF-a	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
or	NULL
medium	NULL
alone	NULL
as	NULL
a	NULL
positive	NULL
or	NULL
a	NULL
negative	NULL
control	NULL
,	NULL
respectively	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
preincubated	NULL
with	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
cold	NULL
wild-	NULL
or	NULL
mutant-type	NULL
NF-kB	NULL
competitor	NULL
oligonucleotides	NULL
and	NULL
were	NULL
treated	NULL
with	NULL
a	NULL
*°P-labeled	NULL
wild-type	NULL
NF-xB	NULL
oligonucleotide	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-specific	NULL
band	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
arrow	NULL
{	NULL
Janes	NULL
8	NULL
,	NULL
10	NULL
,	NULL
11	NULL
,	NULL
and	NULL
13	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Analysis	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
components	NULL
by	NULL
supershift	NULL
assay	NULL
.	NULL

ACH-2/0X40	NULL
#	NULL
10	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PFA-fixed	NULL
SV-T2/gp34	NULL
cells	NULL
or	NULL
TNF-	NULL
«	NULL
.	NULL

Each	NULL
nuclear	NULL
extract	NULL
was	NULL
preincubated	NULL
with	NULL
the	NULL
anti-p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
,	NULL
c-Rel	NULL
,	NULL
or	NULL
Rel-B	NULL
Ab	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
then	NULL
was	NULL
treated	NULL
with	NULL
a	NULL
*°P-labeled	NULL
wild-type	NULL
NF-xB	NULL
oligonucleotide	NULL
.	NULL

The	NULL
arrow	NULL
indicates	NULL
the	NULL
band	NULL
.	NULL

The	NULL
lower	NULL
and	NULL
upper	NULL
open	NULL
arrowheads	NULL
indicate	NULL
the	NULL
bands	NULL
resulting	NULL
from	NULL
the	NULL
supershift	NULL
with	NULL
the	NULL
anti-p50	NULL
or	NULL
p65	NULL
Ab	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
5	NULL
,	NULL
10	NULL
,	NULL
and	NULL
12	NULL
)	NULL
.	NULL

Representative	NULL
results	NULL
are	NULL
shown	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

stimulated	NULL
ACH-2/0X40	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
Abs	NULL
that	NULL
specifically	NULL
recognize	NULL
the	NULL
following	NULL
members	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
:	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
,	NULL
c-Rel	NULL
,	NULL
and	NULL
Rel-B	NULL
.	NULL

The	NULL
band	NULL
was	NULL
supershifted	NULL
by	NULL
p50	NULL
Ab	NULL
and	NULL
also	NULL
by	NULL
p65	NULL
Ab	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
band	NULL
contained	NULL
transactivating	NULL
p50	NULL
and	NULL
p65	NULL
(	NULL
Fig	NULL
:	NULL
5B	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
,	NULL
open	NULL
arrowheads	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
TNF-a	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
11	NULL
to	NULL
13	NULL
;	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lanes	NULL
10	NULL
and	NULL
12	NULL
)	NULL
.	NULL

We	NULL
also	NULL
obtained	NULL
reminiscent	NULL
results	NULL
in	NULL
other	NULL
cells	NULL
,	NULL
ie	NULL
.	NULL

,	NULL
ACH-2/0X40	NULL
#	NULL
4	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
NF-kB	NULL
bands	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
gp34-stimulated	NULL
ACH-2/mock	NULL
#	NULL
7	NULL
cells	NULL
or	NULL
ACH-2	NULL
cell	NULL
line	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

OX40	NULL
triggering	NULL
by	NULL
gp34	NULL
expressed	NULL
on	NULL
HTLV-1*	NULL
T	NULL
cells	NULL
enhances	NULL
HIV-1	NULL
production	NULL
from	NULL
HIV-l-infected	NULL
primary	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Finally	NULL
,	NULL
primary	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
acutely	NULL
infected	NULL
with	NULL
wild-type	NULL
or	NULL
NF-	NULL
«	NULL
B	NULL
mutant	NULL
HIV-1yn	NULL
;	NULL
,	NULL
,	NULL
were	NULL
cocultured	NULL
with	NULL
PFA-fixed	NULL
gp34*	NULL
MT	NULL
-2	NULL
cells	NULL
or	NULL
SV-T2/gp34	NULL
cells	NULL
.	NULL

On	NULL
days	NULL
3	NULL
,	NULL
4	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
after	NULL
cocultivation	NULL
,	NULL
p24	NULL
levels	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
were	NULL
monitored	NULL
.	NULL

Cocultivation	NULL
with	NULL
PFA-fixed	NULL
MT-2	NULL
cells	NULL
resulted	NULL
in	NULL
the	NULL
enhancement	NULL
of	NULL
wild-type	NULL
HIV-1	NULL
production	NULL
from	NULL
CD4*	NULL
T	NULL
cells	NULL
on	NULL
days	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
.	NULL

Dramatic	NULL
augmentation	NULL
of	NULL
HIV-1	NULL
production	NULL
by	NULL
gp34	NULL
was	NULL
seen	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
infected	NULL
with	NULL
T-cell-line-tropic	NULL
HIV-1	NULL
.	NULL

The	NULL
enhanced	NULL
HIV-1	NULL
production	NULL
was	NULL
inhibited	NULL
by	NULL
more	NULL
than	NULL
50	NULL
%	NULL
by	NULL
pre-treatment	NULL
of	NULL
PFA-fixed	NULL
MT	NULL
-2	NULL
cells	NULL
with	NULL
anti-gp34	NULL
neutralizing	NULL
MAb	NULL
(	NULL
5A8	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
also	NULL
obtained	NULL
in	NULL
another	NULL
stimulation	NULL
system	NULL
with	NULL
PFA-fixed	NULL
SV-T2/	NULL
gp34	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

These	NULL
results	NULL
showed	NULL
that	NULL
stimulation	NULL
of	NULL
OX40*	NULL
primary	NULL
T	NULL
cells	NULL
acutely	NULL
infected	NULL
with	NULL
HIV-1	NULL
with	NULL
gp34	NULL
enhanced	NULL
HIV-1	NULL
production	NULL
.	NULL

Interestingly	NULL
,	NULL
NF-	NULL
«	NULL
xB	NULL
mutant	NULL
HIV-1	NULL
production	NULL
was	NULL
also	NULL
enhanced	NULL
by	NULL
cocultivation	NULL
with	NULL
PFA-fixed	NULL
MT-2	NULL
cells	NULL
or	NULL
SV-T2/gp34	NULL
cells	NULL
on	NULL
days	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
,	NULL
although	NULL
stimulation	NULL
was	NULL
less	NULL
efficient	NULL
.	NULL

The	NULL
enhanced	NULL
HIV-1	NULL
production	NULL
was	NULL
significantly	NULL
inhibited	NULL
by	NULL
5A¥8	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
showed	NULL
that	NULL
sites	NULL
other	NULL
than	NULL
those	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
were	NULL
also	NULL
involved	NULL
in	NULL
primary	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

DISCUSSION	NULL
AIDS	NULL
is	NULL
a	NULL
clinically	NULL
multifaceted	NULL
disease	NULL
,	NULL
and	NULL
primary	NULL
infection	NULL
with	NULL
HIV	NULL
is	NULL
usually	NULL
followed	NULL
by	NULL
a	NULL
variably	NULL
prolonged	NULL
period	NULL
of	NULL
clinical	NULL
latency	NULL
.	NULL

Multiple	NULL
factors	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
complex	NULL
interplay	NULL
between	NULL
HIV	NULL
and	NULL
host	NULL
anti-HIV	NULL
immune	NULL
responses	NULL
.	NULL

It	NULL
is	NULL
thus	NULL
important	NULL
to	NULL
understand	NULL
the	NULL
underlying	NULL
mechanisms	NULL
of	NULL
activation	NULL
of	NULL
the	NULL
large	NULL
pool	NULL
of	NULL
latently	NULL
infected	NULL
cells	NULL
and	NULL
the	NULL
progressive	NULL
destruction	NULL
of	NULL
lymphoid	NULL
tissues	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
HIV-1	NULL
expression	NULL
is	NULL
augmented	NULL
through	NULL
signaling	NULL
from	NULL
some	NULL
members	NULL
of	NULL
the	NULL
TNF/TNFR	NULL
superfamily	NULL
,	NULL
including	NULL
TNF/TNFR	NULL
(	NULL
8	NULL
,	NULL
23	NULL
,	NULL
24	NULL
)	NULL
,	NULL
CD30L/CD30	NULL
(	NULL
4	NULL
,	NULL
21	NULL
)	NULL
,	NULL
and	NULL
4-1BBL/4-1BB	NULL
(	NULL
46	NULL
)	NULL
,	NULL
and	NULL
some	NULL
of	NULL
the	NULL
cytokine-recep-tor	NULL
systems	NULL
such	NULL
as	NULL
IL-1/IL-IR	NULL
(	NULL
33	NULL
)	NULL
and	NULL
IL-6/IL-6R	NULL
(	NULL
35	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
stimulation	NULL
of	NULL
OX40	NULL
with	NULL
gp34	NULL
in	NULL
HIV-l-infected	NULL
primary	NULL
T	NULL
cells	NULL
and	NULL
a	NULL
chronically	NULL
infected	NULL
ACH-2/0X40	NULL
cells	NULL
leads	NULL
to	NULL
enhanced	NULL
HIV-1	NULL
expression	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
the	NULL
production	NULL
of	NULL
HIV-1	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
the	NULL
molecular	NULL
mechanisms	NULL
by	NULL
which	NULL
gp34-OX40	NULL
interaction	NULL
activated	NULL
HIV-1	NULL
expression	NULL
in	NULL
ACH-2/0X40	NULL
cells	NULL
and	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
xB	NULL
sites	NULL
present	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
are	NULL
required	NULL
for	NULL
HIV-1	NULL
transcription	NULL
in	NULL
this	NULL
system	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
activity	NULL
obtained	NULL
using	NULL
HIV-1	NULL
LTR-luc	NULL
plasmids	NULL
lacking	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
strongly	NULL
suggests	NULL
that	NULL
OX40	NULL
stimulation	NULL
by	NULL
gp34	NULL
proceeds	NULL
primarily	NULL
through	NULL
«	NULL
B-binding	NULL
sites	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
have	NULL
observed	NULL
that	NULL
two	NULL
NF-kB	NULL
components	NULL
,	NULL
p50	NULL
and	NULL
p65	NULL
subunits	NULL
,	NULL
are	NULL
induced	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
xB	NULL
sites	NULL
upon	NULL
OX40	NULL
stimulation	NULL
of	NULL
ACH-2/0X40	NULL
cells	NULL
in	NULL
EMSAs	NULL
and	NULL
supershift	NULL
assays	NULL
.	NULL

All	NULL
of	NULL
these	NULL
data	NULL
support	NULL
the	NULL
notion	NULL
that	NULL
NF-kB	NULL
activation	NULL
is	NULL
responsible	NULL
for	NULL
enhanced	NULL
HIV-1	NULL
replication	NULL
in	NULL
HIV-1-infected	NULL
cells	NULL
by	NULL
OX40	NULL
and	NULL
gp34	NULL
interaction	NULL
in	NULL
ACH-2/0X40	NULL
cells	NULL
.	NULL

Enhancement	NULL
of	NULL
virus	NULL
production	NULL
by	NULL
gp34-OX40	NULL
interaction	NULL
was	NULL
also	NULL
reproduced	NULL
in	NULL
primary	NULL
CD4*	NULL
T	NULL
cells	NULL
acutely	NULL
infected	NULL
with	NULL
HIV-1	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
strongly	NULL
suggested	NULL
that	NULL
a	NULL
similar	NULL
event	NULL
may	NULL
occur	NULL
in	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
A	NULL
.	NULL

ENHANCED	NULL
HIV-1	NULL
PRODUCTION	NULL
BY	NULL
OX40	NULL
COSTIMULATION	NULL
_	NULL
6755	NULL
HIV-1NL4-3	NULL
(	NULL
WT	NULL
)	NULL
25	NULL
7	NULL
[	NULL
C	NULL
]	NULL
+	NULL
Medium	NULL
+	NULL
PBS	NULL
20	NULL
4	NULL
-	NULL
F	NULL
]	NULL
+	NULL
Medium	NULL
+	NULL
5A8	NULL
B	NULL
+-	NULL
mr24	NULL
pes	NULL
15	NULL
7	NULL
+	NULL
MT-2	NULL
+	NULL
Cont	NULL
.	NULL

+	NULL
MT-2	NULL
+	NULL
5A8	NULL
p24	NULL
concentration	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

[	NULL
A	NULL
+	NULL
Medium	NULL
+	NULL
Cont	NULL
.	NULL

T	NULL
[	NULL
]	NULL
+	NULL
SV-T2/mock	NULL
+	NULL
PBS	NULL
[	NULL
Z	NULL
]	NULL
+	NULL
SV-T2/mock	NULL
+	NULL
Cont	NULL
.	NULL

4	NULL
-	NULL
+	NULL
SV-T2/mock	NULL
+	NULL
5A8	NULL
R	NULL
+	NULL
sv-T2/gp34	NULL
+	NULL
PBS	NULL
TT	NULL
3	NULL
4	NULL
[	NULL
N	NULL
+	NULL
SV-T2/gp34	NULL
+	NULL
Cont	NULL
.	NULL

Q	NULL
+	NULL
SV-T2/gp34	NULL
+	NULL
5A8	NULL
Q	NULL
H-	NULL
§	NULL
a	NULL
§	NULL
:	NULL
MBP	NULL
-	NULL
N	NULL
2B	NULL
A	NULL
P0	NULL
§	NULL
o	NULL
-	NULL
A	NULL
99	NULL
8	NULL
5	NULL
6	NULL
7	NULL
Days	NULL
HIV-1NL4-3	NULL
(	NULL
AkB	NULL
)	NULL
25	NULL
/	NULL
[	NULL
-	NULL
]	NULL
+	NULL
Medium	NULL
+	NULL
PBS	NULL
[	NULL
Z	NULL
]	NULL
+	NULL
Medium	NULL
+	NULL
Cont	NULL
.	NULL

20	NULL
-	NULL
+	NULL
Medium	NULL
+	NULL
5A8	NULL
R	NULL
+-	NULL
vtT-2	NULL
+	NULL
pss	NULL
154	NULL
-	NULL
NN	NULL
+	NULL
MT-2	NULL
+	NULL
Cont	NULL
.	NULL

+	NULL
MT-2	NULL
+	NULL
5A8	NULL
p24	NULL
concentration	NULL
(	NULL
ng/ml	NULL
!	NULL
)	NULL

57	NULL
]	NULL
[	NULL
]	NULL
+SV-T2/mock	NULL
+	NULL
PBS	NULL
FA	NULL
+	NULL
SV-T2/mock	NULL
+	NULL
Cont	NULL
.	NULL

4	NULL
|	NULL
EY	NULL
+	NULL
SV-T2/mock	NULL
+	NULL
5A8	NULL
I	NULL
+	NULL
sv-T27gp34	NULL
+	NULL
PBS	NULL
3	NULL
4	NULL
RY	NULL
+	NULL
SV-T2/gp34	NULL
+	NULL
Cont	NULL
.	NULL

+	NULL
SV-T2/gp34	NULL
+	NULL
5A8	NULL
Days	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Enhanced	NULL
HIV-1	NULL
expression	NULL
in	NULL
primary	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
by	NULL
coculture	NULL
with	NULL
gp34-expressing	NULL
cells	NULL
.	NULL

Anti-CD3	NULL
MAb-stimulated	NULL
primary	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
cultured	NULL
for	NULL
8	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rhIL-2	NULL
and	NULL
rhIL-4	NULL
were	NULL
infected	NULL
with	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
(	NULL
A	NULL
)	NULL
or	NULL
NF-	NULL
«	NULL
xB	NULL
mutant	NULL
(	NULL
AkB	NULL
)	NULL
(	NULL
B	NULL
)	NULL
HIV-ly	NULL
;	NULL
4	NULL
;	NULL
at	NULL
an	NULL
MOI	NULL
of	NULL
0.002	NULL
.	NULL

They	NULL
were	NULL
cultured	NULL
either	NULL
alone	NULL
or	NULL
with	NULL
a	NULL
half	NULL
number	NULL
of	NULL
PFA-fixed	NULL
gp34*	NULL
MT	NULL
-2	NULL
cells	NULL
,	NULL
SV-T2/gp34	NULL
cells	NULL
,	NULL
or	NULL
SV-T2/mock	NULL
cells	NULL
pretreated	NULL
with	NULL
or	NULL
without	NULL
MAb	NULL
(	NULL
10	NULL
ug	NULL
of	NULL
anti-gp34	NULL
neutralizing	NULL
MAb	NULL
[	NULL
5A8	NULL
]	NULL
per	NULL
ml	NULL
or	NULL
a	NULL
subtype-matched	NULL
control	NULL
MAb	NULL
[	NULL
Cont	NULL
.	NULL
]	NULL

)	NULL
.	NULL

After	NULL
HIV-1	NULL
infection	NULL
,	NULL
culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
to	NULL
measure	NULL
the	NULL
HIV-1	NULL
p24	NULL
level	NULL
.	NULL

The	NULL
results	NULL
are	NULL
the	NULL
means	NULL
+	NULL
standard	NULL
error	NULL
of	NULL
the	NULL
mean	NULL
for	NULL
values	NULL
obtained	NULL
in	NULL
triplicate	NULL
.	NULL

Representative	NULL
results	NULL
are	NULL
shown	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

vivo	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
in	NULL
this	NULL
experimental	NULL
system	NULL
,	NULL
not	NULL
only	NULL
wild-type	NULL
but	NULL
also	NULL
NF-	NULL
«	NULL
B	NULL
mutant	NULL
HIV-ly	NULL
;	NULL
4	NULL
;	NULL
were	NULL
enhanced	NULL
to	NULL
produce	NULL
virus	NULL
upon	NULL
stimulation	NULL
with	NULL
OX40	NULL
,	NULL
although	NULL
the	NULL
mutant	NULL
virus	NULL
was	NULL
less	NULL
efficiently	NULL
enhanced	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
sites	NULL
other	NULL
than	NULL
those	NULL
for	NULL
NF-kB	NULL
binding	NULL
were	NULL
also	NULL
involved	NULL
in	NULL
primary	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
address	NULL
further	NULL
whether	NULL
this	NULL
difference	NULL
is	NULL
due	NULL
to	NULL
either	NULL
the	NULL
difference	NULL
between	NULL
acute	NULL
and	NULL
chronic	NULL
infection	NULL
or	NULL
the	NULL
difference	NULL
between	NULL
primary	NULL
T	NULL
cells	NULL
and	NULL
cell	NULL
line	NULL
cells	NULL
.	NULL

It	NULL
was	NULL
of	NULL
note	NULL
that	NULL
apparent	NULL
apoptosis	NULL
was	NULL
observed	NULL
in	NULL
ACH-2/0X40	NULL
cells	NULL
when	NULL
they	NULL
were	NULL
stimulated	NULL
by	NULL
gp34	NULL
.	NULL

This	NULL
result	NULL
is	NULL
quite	NULL
different	NULL
from	NULL
the	NULL
case	NULL
of	NULL
CD30L-stimulated	NULL
CD30*	NULL
ACH-2	NULL
cells	NULL
,	NULL
in	NULL
which	NULL
no	NULL
cell	NULL
death	NULL
but	NULL
rather	NULL
a	NULL
slight	NULL
stimulation	NULL
of	NULL
cell	NULL
proliferation	NULL
was	NULL
observed	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
OX40	NULL
signaling	NULL
on	NULL
cells	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
TNF-	NULL
«	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
of	NULL
particular	NULL
importance	NULL
to	NULL
investigate	NULL
a	NULL
potential	NULL
role	NULL
of	NULL
the	NULL
OX40/gp34	NULL
system	NULL
in	NULL
vivo	NULL
,	NULL
not	NULL
only	NULL
from	NULL
the	NULL
aspect	NULL
of	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
but	NULL
also	NULL
in	NULL
light	NULL
of	NULL
the	NULL
killing	NULL
of	NULL
6756	NULL
TAKAHASHI	NULL
ET	NULL
AL	NULL
.	NULL

HIV-1-infected	NULL
cells	NULL
as	NULL
observed	NULL
in	NULL
the	NULL
TNF/TNFR	NULL
model	NULL
(	NULL
24	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
in	NULL
the	NULL
stimulation	NULL
system	NULL
of	NULL
ACH-2/	NULL
OX40	NULL
cells	NULL
by	NULL
gp34	NULL
or	NULL
TNF-	NULL
«	NULL
,	NULL
since	NULL
FasL-neutralizing	NULL
MAb	NULL
could	NULL
not	NULL
inhibit	NULL
apoptosis	NULL
these	NULL
apoptosis	NULL
may	NULL
be	NULL
independent	NULL
of	NULL
the	NULL
FasL/Fas	NULL
system	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
extensive	NULL
HIV-1	NULL
replication	NULL
occurs	NULL
in	NULL
secondary	NULL
lymphoid	NULL
organs	NULL
,	NULL
where	NULL
CD4	NULL
*	NULL
T-helper	NULL
cells	NULL
meet	NULL
antigens	NULL
presented	NULL
by	NULL
antigen-presenting	NULL
cells	NULL
(	NULL
APC	NULL
)	NULL
(	NULL
9	NULL
,	NULL
14	NULL
)	NULL
and	NULL
are	NULL
activated	NULL
to	NULL
express	NULL
OX40	NULL
(	NULL
31	NULL
)	NULL
.	NULL

DC	NULL
are	NULL
the	NULL
most	NULL
potent	NULL
APC	NULL
in	NULL
vivo	NULL
.	NULL

Generally	NULL
,	NULL
it	NULL
is	NULL
considered	NULL
that	NULL
immature	NULL
DC	NULL
in	NULL
peripheral	NULL
tissues	NULL
capture	NULL
antigens	NULL
efficiently	NULL
and	NULL
have	NULL
the	NULL
unique	NULL
capacity	NULL
to	NULL
subsequently	NULL
migrate	NULL
to	NULL
the	NULL
T-cell	NULL
areas	NULL
of	NULL
secondary	NULL
lymphoid	NULL
organs	NULL
(	NULL
2	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
gp34	NULL
is	NULL
predominantly	NULL
expressed	NULL
on	NULL
APC	NULL
,	NULL
such	NULL
as	NULL
DC	NULL
and	NULL
B	NULL
cells	NULL
,	NULL
suggests	NULL
the	NULL
importance	NULL
of	NULL
OX40-gp34	NULL
in	NULL
HIV-1	NULL
productive	NULL
infection	NULL
.	NULL

Furthermore	NULL
,	NULL
gp34	NULL
on	NULL
DC	NULL
was	NULL
shown	NULL
to	NULL
induce	NULL
differentiation	NULL
of	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
to	NULL
IL-4-secreting	NULL
type	NULL
2	NULL
helper	NULL
phenotype	NULL
(	NULL
31	NULL
)	NULL
,	NULL
in	NULL
which	NULL
virulent	NULL
T-	NULL
cell-line-tropic	NULL
HIV-1	NULL
can	NULL
proliferate	NULL
preferentially	NULL
(	NULL
43	NULL
)	NULL
.	NULL

This	NULL
may	NULL
facilitate	NULL
the	NULL
production	NULL
of	NULL
Abs	NULL
specific	NULL
to	NULL
HIV-1	NULL
antigens	NULL
from	NULL
B	NULL
cells	NULL
by	NULL
means	NULL
of	NULL
IL-4	NULL
secreted	NULL
from	NULL
type	NULL
2	NULL
helper	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
since	NULL
gp34	NULL
has	NULL
been	NULL
shown	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
of	NULL
VEC	NULL
(	NULL
16	NULL
)	NULL
,	NULL
interaction	NULL
of	NULL
blood	NULL
OX40*	NULL
T	NULL
cells	NULL
infected	NULL
with	NULL
HIV-1	NULL
may	NULL
be	NULL
activated	NULL
by	NULL
gp34*	NULL
VEC	NULL
,	NULL
which	NULL
may	NULL
enhance	NULL
HIV-1	NULL
production	NULL
in	NULL
inflammatory	NULL
sites	NULL
.	NULL

The	NULL
OX40-gp34	NULL
interaction	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
bidirectional	NULL
signals	NULL
.	NULL

For	NULL
example	NULL
,	NULL
gp34	NULL
stimulation	NULL
by	NULL
OX40	NULL
transduced	NULL
a	NULL
signal	NULL
in	NULL
DC	NULL
,	NULL
which	NULL
resulted	NULL
in	NULL
enhanced	NULL
TNF-a	NULL
and	NULL
IL-18	NULL
production	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Since	NULL
these	NULL
cytokines	NULL
are	NULL
potent	NULL
stimulators	NULL
of	NULL
HIV-1	NULL
production	NULL
from	NULL
infected	NULL
T	NULL
cells	NULL
,	NULL
HIV-1	NULL
infected	NULL
OX40*	NULL
T	NULL
cells	NULL
contacting	NULL
gp34	NULL
``	NULL
DC	NULL
may	NULL
receive	NULL
signals	NULL
not	NULL
only	NULL
from	NULL
OX40	NULL
stimulation	NULL
but	NULL
also	NULL
from	NULL
these	NULL
cytokines	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
would	NULL
be	NULL
interesting	NULL
to	NULL
examine	NULL
whether	NULL
the	NULL
activation	NULL
of	NULL
DC	NULL
with	NULL
OX40	NULL
may	NULL
enhance	NULL
the	NULL
expression	NULL
of	NULL
DC-SIGN	NULL
,	NULL
which	NULL
is	NULL
responsible	NULL
for	NULL
capturing	NULL
HIV-1	NULL
,	NULL
in	NULL
the	NULL
periphery	NULL
and	NULL
facilitating	NULL
its	NULL
transport	NULL
to	NULL
secondary	NULL
lymphoid	NULL
organs	NULL
rich	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
thus	NULL
enhance	NULL
infection	NULL
in	NULL
trans	NULL
of	NULL
these	NULL
target	NULL
cells	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Besides	NULL
DC	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
HUVEC	NULL
(	NULL
16	NULL
,	NULL
28	NULL
,	NULL
30	NULL
)	NULL
,	NULL
it	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
HTLV-infected	NULL
cells	NULL
express	NULL
gp34	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
of	NULL
interest	NULL
to	NULL
study	NULL
whether	NULL
such	NULL
gp34~*	NULL
HTLV	NULL
*	NULL
T	NULL
cells	NULL
enhance	NULL
HIV-1	NULL
production	NULL
in	NULL
patients	NULL
harboring	NULL
both	NULL
HTLV	NULL
and	NULL
HIV-1	NULL
.	NULL

Recent	NULL
in	NULL
vitro	NULL
studies	NULL
showed	NULL
that	NULL
(	NULL
i	NULL
)	NULL
noninfectious	NULL
HTLV-1	NULL
virions	NULL
induced	NULL
the	NULL
production	NULL
of	NULL
large	NULL
quantities	NULL
of	NULL
HIV-1	NULL
from	NULL
T	NULL
cells	NULL
by	NULL
mitogenic	NULL
stimulation	NULL
(	NULL
47	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
primary	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
treated	NULL
with	NULL
soluble	NULL
Tax	NULL
protein	NULL
and	NULL
cell-free	NULL
supernatants	NULL
from	NULL
HTLV-l-infected	NULL
MT-2	NULL
cell	NULL
cultures	NULL
,	NULL
containing	NULL
B-chemokines	NULL
of	NULL
RANTES	NULL
(	NULL
regulated	NULL
upon	NULL
activation	NULL
,	NULL
normal	NULL
T-cell	NULL
expressed	NULL
and	NULL
se-creted	NULL
)	NULL
,	NULL
macrophage	NULL
inflammatory	NULL
protein	NULL
1	NULL
«	NULL
(	NULL
MIP-1	NULL
«	NULL
)	NULL
,	NULL
and	NULL
MIP-18	NULL
became	NULL
highly	NULL
susceptible	NULL
to	NULL
T-cell-line-tropic	NULL
HIV-1	NULL
(	NULL
29	NULL
)	NULL
;	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
coinfection	NULL
of	NULL
monocyte-derived	NULL
macrophages	NULL
with	NULL
T-cell-line-tropic	NULL
HIV-1	NULL
and	NULL
HTLV-1	NULL
significantly	NULL
enhanced	NULL
HIV-1	NULL
replication	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Since	NULL
Tax	NULL
induces	NULL
both	NULL
OX40	NULL
and	NULL
gp34	NULL
(	NULL
15	NULL
,	NULL
26	NULL
,	NULL
34	NULL
)	NULL
,	NULL
OX40-gp34	NULL
interaction	NULL
induced	NULL
by	NULL
Tax	NULL
may	NULL
enhance	NULL
HIV-l-production	NULL
.	NULL

Furthermore	NULL
,	NULL
since	NULL
MT-2	NULL
culture	NULL
supernatants	NULL
contain	NULL
soluble	NULL
gp34	NULL
(	NULL
Y.	NULL
Tanaka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
unpublished	NULL
data	NULL
)	NULL
,	NULL
it	NULL
will	NULL
be	NULL
worthwhile	NULL
to	NULL
test	NULL
whether	NULL
an	NULL
anti-gp34	NULL
MAb	NULL
,	NULL
58	NULL
,	NULL
can	NULL
inhibit	NULL
such	NULL
enhancement	NULL
.	NULL

We	NULL
showed	NULL
that	NULL
OX40-gp34	NULL
interaction	NULL
plays	NULL
an	NULL
important	NULL
J.	NULL
Virou	NULL
.	NULL

role	NULL
in	NULL
enhancing	NULL
HIV-1	NULL
replication	NULL
in	NULL
vitro	NULL
.	NULL

Since	NULL
in	NULL
HIV-1-infected	NULL
patients	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
activated	NULL
to	NULL
express	NULL
OX40	NULL
in	NULL
addition	NULL
to	NULL
CD4O0L	NULL
and	NULL
Fas	NULL
(	NULL
37	NULL
)	NULL
,	NULL
it	NULL
is	NULL
speculated	NULL
that	NULL
these	NULL
OX40*	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
peripheral	NULL
blood	NULL
and	NULL
in	NULL
lymphoid	NULL
organs	NULL
,	NULL
where	NULL
cell-to-cell	NULL
contact	NULL
can	NULL
easily	NULL
occur	NULL
,	NULL
can	NULL
be	NULL
co-stimulated	NULL
by	NULL
gp34	NULL
in	NULL
vivo	NULL
.	NULL

This	NULL
potential	NULL
mechanism	NULL
of	NULL
induction	NULL
of	NULL
HIV-1	NULL
expression	NULL
from	NULL
both	NULL
acutely	NULL
and	NULL
latently	NULL
infected	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
by	NULL
direct	NULL
cellular	NULL
interaction	NULL
may	NULL
play	NULL
a	NULL
pivotal	NULL
role	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
HIV-1	NULL
disease	NULL
.	NULL

Therefore	NULL
,	NULL
intervention	NULL
of	NULL
interactions	NULL
between	NULL
OX40	NULL
and	NULL
gp34	NULL
will	NULL
be	NULL
considered	NULL
as	NULL
a	NULL
potentially	NULL
new	NULL
therapeutic	NULL
strategy	NULL
for	NULL
inhibiting	NULL
enhanced	NULL
HIV-1	NULL
replication	NULL
in	NULL
vivo	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Y.	NULL
Tsunetsugu-Yokota	NULL
of	NULL
National	NULL
Institute	NULL
of	NULL
Infectious	NULL
Diseases	NULL
for	NULL
gifts	NULL
of	NULL
mutant	NULL
viruses	NULL
,	NULL
H.	NULL
Niwa	NULL
of	NULL
Osaka	NULL
University	NULL
for	NULL
gifts	NULL
of	NULL
the	NULL
pCAGIPuro	NULL
vector	NULL
,	NULL
S.	NULL
Yamaoka	NULL
for	NULL
helpful	NULL
suggestions	NULL
,	NULL
M.	NULL
Hoshi	NULL
and	NULL
N.	NULL
Misawa	NULL
for	NULL
technical	NULL
assistance	NULL
,	NULL
and	NULL
S.	NULL
R.	NULL
Jennings	NULL
of	NULL
Louisiana	NULL
State	NULL
University	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
grants	NULL
from	NULL
Health	NULL
Sciences	NULL
of	NULL
Organization	NULL
for	NULL
Drug	NULL
ADR	NULL
Relief	NULL
,	NULL
R	NULL
&	NULL
D	NULL
Promotion	NULL
and	NULL
Product	NULL
Review	NULL
of	NULL
Japan	NULL
,	NULL
and	NULL
CREST	NULL
(	NULL
Core	NULL
Research	NULL
for	NULL
Evolutional	NULL
Science	NULL
and	NULL
Technology	NULL
)	NULL
of	NULL
The	NULL
Japan	NULL
Science	NULL
and	NULL
Technology	NULL
Corporation	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Baker	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
E.	NULL
P.	NULL
Reddy	NULL
.	NULL

1998	NULL
.	NULL

Modulation	NULL
of	NULL
life	NULL
and	NULL
death	NULL
by	NULL
the	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
.	NULL

Oncogene	NULL
17:3261-3270	NULL
.	NULL

2	NULL
.	NULL

Banchereau	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Steinman	NULL
.	NULL

1998	NULL
.	NULL

Dendritic	NULL
cells	NULL
and	NULL
the	NULL
control	NULL
of	NULL
immunity	NULL
.	NULL

Nature	NULL
392:245-252	NULL
.	NULL

3	NULL
.	NULL

Baum	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
R.	NULL
B.	NULL
Gayle	NULL
III	NULL
.	NULL

,	NULL
F.	NULL
Ramsdell	NULL
,	NULL
S.	NULL
Srinivasan	NULL
,	NULL
R.	NULL
A.	NULL
Sorensen	NULL
,	NULL
M.	NULL
L.	NULL
Watson	NULL
,	NULL
M.	NULL
F.	NULL
Seldin	NULL
,	NULL
E.	NULL
Baker	NULL
,	NULL
G.	NULL
R.	NULL
Sutherland	NULL
,	NULL
K.	NULL
N.	NULL
Clifford	NULL
,	NULL
M.	NULL
R.	NULL
Alderson	NULL
,	NULL
R.	NULL
G.	NULL
Goodwin	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Fanslow	NULL
.	NULL

1994	NULL
.	NULL

Molecular	NULL
characterization	NULL
of	NULL
murine	NULL
and	NULL
human	NULL
OX40/OX40	NULL
ligand	NULL
systems	NULL
:	NULL
identification	NULL
of	NULL
a	NULL
human	NULL
OX40	NULL
ligand	NULL
as	NULL
the	NULL
HTLV-1-regulated	NULL
protein	NULL
gp34	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13	NULL
:	NULL
3992-4001	NULL
.	NULL

4	NULL
.	NULL

Biswas	NULL
,	NULL
P.	NULL
,	NULL
C.	NULL
A.	NULL
Smith	NULL
,	NULL
D.	NULL
Goletti	NULL
,	NULL
E.	NULL
C.	NULL
Hardy	NULL
,	NULL
R.	NULL
W.	NULL
Jackson	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1995	NULL
.	NULL

Cross-linking	NULL
of	NULL
CD30	NULL
induces	NULL
HIV	NULL
expression	NULL
in	NULL
chronically	NULL
infected	NULL
T	NULL
cells	NULL
.	NULL

Immunity	NULL
2:587-596	NULL
.	NULL

5	NULL
.	NULL

Bradford	NULL
,	NULL
M.	NULL
M.	NULL
1976	NULL
.	NULL

A	NULL
rapid	NULL
and	NULL
sensitive	NULL
method	NULL
for	NULL
the	NULL
quantitation	NULL
of	NULL
microgram	NULL
quantities	NULL
of	NULL
protein	NULL
utilizing	NULL
the	NULL
principle	NULL
of	NULL
protein-dye	NULL
bind-ing	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

72:248-254	NULL
.	NULL

6	NULL
.	NULL

Bressler	NULL
,	NULL
P.	NULL
,	NULL
G.	NULL
Pantaleo	NULL
,	NULL
A.	NULL
Demaria	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1991	NULL
.	NULL

Anti-CD2	NULL
receptor	NULL
antibodies	NULL
activate	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

147:2290-2294	NULL
.	NULL

7	NULL
.	NULL

Clouse	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
D.	NULL
Powell	NULL
,	NULL
I.	NULL
Washington	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
K.	NULL
Strebel	NULL
,	NULL
W.	NULL
Farrar	NULL
,	NULL
P.	NULL
Barstad	NULL
,	NULL
J.	NULL
Kovacs	NULL
,	NULL
A.	NULL
S.	NULL
Fauci	NULL
,	NULL
and	NULL
T.	NULL
M.	NULL
Folks	NULL
.	NULL

1989	NULL
.	NULL

Monokine	NULL
regulaton	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
expression	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
human	NULL
T	NULL
cell	NULL
clone	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:431-438	NULL
.	NULL

8	NULL
.	NULL

Dub	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
W.	NULL
J.	NULL
Maury	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
A.	NULL
S.	NULL
Fauci	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
activates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
through	NULL
induction	NULL
of	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:5974-5978	NULL
.	NULL

9	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
1993	NULL
.	NULL

Multifactorial	NULL
nature	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
disease	NULL
:	NULL
implications	NULL
for	NULL
therapy	NULL
.	NULL

Science	NULL
262:1011-1018	NULL
.	NULL

10	NULL
.	NULL

Geijtenbeek	NULL
,	NULL
T.	NULL
B.	NULL
H.	NULL
,	NULL
D.	NULL
S.	NULL
Kwon	NULL
,	NULL
R.	NULL
Torensma	NULL
,	NULL
S.	NULL
J.	NULL
van	NULL
Vliet	NULL
,	NULL
G.	NULL
C.	NULL
F.	NULL
van	NULL
Duijnhoven	NULL
,	NULL
J.	NULL
Middel	NULL
,	NULL
I.	NULL
L.	NULL
M.	NULL
H.	NULL
A.	NULL
Cornelissen	NULL
,	NULL
H.	NULL
S.	NULL
L.	NULL
M.	NULL
Nottet	NULL
,	NULL
V.	NULL
N.	NULL
KewalRamani	NULL
,	NULL
D.	NULL
R.	NULL
Littman	NULL
,	NULL
C.	NULL
G.	NULL
Figdor	NULL
,	NULL
and	NULL
Y.	NULL
van	NULL
Kooyk	NULL
.	NULL

2000	NULL
.	NULL

DC-SIGN	NULL
,	NULL
a	NULL
dendritic	NULL
cell-specific	NULL
HIV-1-binding	NULL
protein	NULL
that	NULL
enhances	NULL
trans-infection	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

Cell	NULL
100:587-597	NULL
.	NULL

11	NULL
.	NULL

Godfrey	NULL
,	NULL
W.	NULL
R.	NULL
,	NULL
F.	NULL
F.	NULL
Fagnoni	NULL
,	NULL
M.	NULL
A.	NULL
Harara	NULL
,	NULL
D.	NULL
Buck	NULL
,	NULL
and	NULL
E.	NULL
G.	NULL
Engleman	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
human	NULL
OX-40	NULL
ligand	NULL
,	NULL
a	NULL
costimulator	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
with	NULL
homology	NULL
to	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:757-762	NULL
.	NULL

12	NULL
.	NULL

Gras	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
Legendre	NULL
,	NULL
R.	NULL
Krzysiek	NULL
,	NULL
D.	NULL
Dormont	NULL
,	NULL
P.	NULL
Galanaud	NULL
,	NULL
and	NULL
Y.	NULL
Richard	NULL
.	NULL

1996	NULL
.	NULL

CD40/CD4O0L	NULL
interactions	NULL
and	NULL
cytokines	NULL
regulate	NULL
HIV	NULL
replication	NULL
in	NULL
B	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Virology	NULL
220:309-319	NULL
.	NULL

13	NULL
.	NULL

Gruss	NULL
,	NULL
H.-J	NULL
.	NULL

,	NULL
and	NULL
S.	NULL
K.	NULL
Dower	NULL
.	NULL

1995	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
ligand	NULL
super-family	NULL
:	NULL
involvement	NULL
in	NULL
the	NULL
pathology	NULL
of	NULL
malignant	NULL
lymphomas	NULL
.	NULL

Blood	NULL
85	NULL
:	NULL
3378-3404	NULL
.	NULL

14	NULL
.	NULL

Haase	NULL
,	NULL
A.	NULL
T.	NULL
1999	NULL
.	NULL

Population	NULL
biology	NULL
of	NULL
HIV-1	NULL
infection	NULL
:	NULL
viral	NULL
and	NULL
CD4*	NULL
T	NULL
cell	NULL
demographics	NULL
and	NULL
dynamics	NULL
in	NULL
lymphatic	NULL
tissues	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

17:625-656	NULL
.	NULL

15	NULL
.	NULL

Higashimura	NULL
,	NULL
N.	NULL
,	NULL
N.	NULL
Takasawa	NULL
,	NULL
Y.	NULL
Tanaka	NULL
,	NULL
M.	NULL
Nakamura	NULL
,	NULL
and	NULL
K.	NULL
Sugamura	NULL
.	NULL

1996	NULL
.	NULL

Induction	NULL
of	NULL
OX40	NULL
,	NULL
a	NULL
receptor	NULL
of	NULL
gp34	NULL
,	NULL
on	NULL
T	NULL
cells	NULL
by	NULL
transacting	NULL
transcriptional	NULL
activator	NULL
,	NULL
Tax	NULL
,	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I.	NULL
Jpn	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

87:227-231	NULL
.	NULL

Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

Imura	NULL
,	NULL
A.	NULL
,	NULL
T.	NULL
Hori	NULL
,	NULL
K.	NULL
Imada	NULL
,	NULL
T.	NULL
Ishikawa	NULL
,	NULL
Y.	NULL
Tanaka	NULL
,	NULL
M.	NULL
Maeda	NULL
,	NULL
S.	NULL
Imamura	NULL
,	NULL
and	NULL
T.	NULL
Uchiyama	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
human	NULL
OX40/gp34	NULL
system	NULL
directly	NULL
mediates	NULL
adhesion	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
to	NULL
vascular	NULL
endothelial	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:2185-2195	NULL
.	NULL

Inoue	NULL
,	NULL
J.	NULL
,	NULL
T.	NULL
Ishida	NULL
,	NULL
N.	NULL
Tsukamoto	NULL
,	NULL
N.	NULL
Kobayashi	NULL
,	NULL
A.	NULL
Naito	NULL
,	NULL
S.	NULL
Azuma	NULL
,	NULL
and	NULL
T.	NULL
Yamamoto	NULL
.	NULL

2000	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
factor	NULL
(	NULL
TRAF	NULL
)	NULL
family	NULL
:	NULL
adaptor	NULL
proteins	NULL
that	NULL
mediate	NULL
cytokine	NULL
signaling	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

254:14-24	NULL
.	NULL

Ishida	NULL
,	NULL
Y.	NULL
,	NULL
Y.	NULL
Agata	NULL
,	NULL
K.	NULL
Shibahara	NULL
,	NULL
and	NULL
T.	NULL
Honjo	NULL
.	NULL

1992	NULL
.	NULL

Induced	NULL
expression	NULL
of	NULL
PD-1	NULL
,	NULL
a	NULL
novel	NULL
member	NULL
of	NULL
the	NULL
immunoglobulin	NULL
gene	NULL
superfamily	NULL
,	NULL
upon	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:3887-3895	NULL
.	NULL

Kawamata	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Hori	NULL
,	NULL
A.	NULL
Imura	NULL
,	NULL
A.	NULL
Takaori-Kondo	NULL
,	NULL
and	NULL
T.	NULL
Uchiyama	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
OX40	NULL
signal	NULL
transduction	NULL
pathways	NULL
leads	NULL
to	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
factor	NULL
(	NULL
TRAF	NULL
)	NULL
2-	NULL
and	NULL
TRAFS-mediated	NULL
NF-kB	NULL
activation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:5808-5814	NULL
.	NULL

Latza	NULL
,	NULL
U.	NULL
,	NULL
H.	NULL
Diirkop	NULL
,	NULL
S.	NULL
Schnittger	NULL
,	NULL
J.	NULL
Ringeling	NULL
,	NULL
F.	NULL
Eitelbach	NULL
,	NULL
M.	NULL
Hummel	NULL
,	NULL
C.	NULL
Fonatsch	NULL
,	NULL
and	NULL
H.	NULL
Stein	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
human	NULL
OX40	NULL
homolog	NULL
:	NULL
cDNA	NULL
struc-ture	NULL
,	NULL
expression	NULL
and	NULL
chromosomal	NULL
assignment	NULL
of	NULL
the	NULL
ACT35	NULL
antigen	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:677-683	NULL
.	NULL

Maggi	NULL
,	NULL
E.	NULL
,	NULL
F.	NULL
Annunziato	NULL
,	NULL
R.	NULL
Manetti	NULL
,	NULL
R.	NULL
Biagiotti	NULL
,	NULL
M.	NULL
G.	NULL
Giudizi	NULL
,	NULL
A.	NULL
Ravina	NULL
,	NULL
F.	NULL
Almerigogna	NULL
,	NULL
N.	NULL
Boiani	NULL
,	NULL
M.	NULL
Alderson	NULL
,	NULL
and	NULL
S.	NULL
Romagnani	NULL
,	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
HIV	NULL
expression	NULL
by	NULL
CD30	NULL
triggering	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
HIV-infected	NULL
individuals	NULL
.	NULL

Immunity	NULL
3:251-255	NULL
.	NULL

Matsumura	NULL
,	NULL
Y.	NULL
,	NULL
T.	NULL
Hori	NULL
,	NULL
S.	NULL
Kawamata	NULL
,	NULL
A.	NULL
Imura	NULL
,	NULL
and	NULL
T.	NULL
Uchiyama	NULL
.	NULL

1999	NULL
.	NULL

Intracellular	NULL
signaling	NULL
of	NULL
gp34	NULL
,	NULL
the	NULL
OX40	NULL
ligand	NULL
:	NULL
induction	NULL
of	NULL
c-jun	NULL
and	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
through	NULL
gp34	NULL
upon	NULL
binding	NULL
of	NULL
its	NULL
receptor	NULL
,	NULL
OX40	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163:3007-3011	NULL
.	NULL

Matsuyama	NULL
,	NULL
T.	NULL
,	NULL
Y.	NULL
H	NULL
to	NULL
,	NULL
T.	NULL
Ol	NULL
to	NULL
,	NULL
K.	NULL
Shi	NULL
N.	NULL
Kobayashi	NULL
,	NULL
and	NULL
N.	NULL
Yamamoto	NULL
.	NULL

1988	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
and	NULL
HIV	NULL
:	NULL
a	NULL
note	NULL
of	NULL
caution	NULL
.	NULL

Lancet	NULL
ii:1364	NULL
.	NULL

Matsuyama	NULL
,	NULL
T.	NULL
,	NULL
Y.	NULL
Hamamoto	NULL
,	NULL
G.	NULL
Soma	NULL
,	NULL
D.	NULL
Mizuno	NULL
,	NULL
N.	NULL
Yamamoto	NULL
,	NULL
and	NULL
N.	NULL
Kobayashi	NULL
.	NULL

1989	NULL
.	NULL

Cytocidal	NULL
effect	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
on	NULL
cells	NULL
chronically	NULL
infected	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
:	NULL
enhancement	NULL
of	NULL
HIV	NULL
replication	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:2504-2509	NULL
.	NULL

Minowada	NULL
,	NULL
J.	NULL
,	NULL
T.	NULL
Ohnuma	NULL
,	NULL
and	NULL
G.	NULL
E.	NULL
Moore	NULL
.	NULL

1972	NULL
.	NULL

Rosctte-forming	NULL
human	NULL
lymphoid	NULL
cell	NULL
lines	NULL
.	NULL

I	NULL
.	NULL

Establishment	NULL
and	NULL
evidence	NULL
for	NULL
origin	NULL
of	NULL
thymus-derived	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

49:891	NULL
.	NULL

Miura	NULL
,	NULL
S.	NULL
,	NULL
K.	NULL
Obtani	NULL
,	NULL
N.	NULL
Numata	NULL
,	NULL
M.	NULL
Niki	NULL
,	NULL
K.	NULL
Ohbo	NULL
,	NULL
Y.	NULL
Ina	NULL
,	NULL
T.	NULL
Gojobori	NULL
,	NULL
Y.	NULL
Tanaka	NULL
,	NULL
H.	NULL
Tozawa	NULL
,	NULL
M.	NULL
Nakamura	NULL
,	NULL
and	NULL
K.	NULL
Sugamura	NULL
.	NULL

1991	NULL
.	NULL

Molecular	NULL
cloning	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
novel	NULL
glycoprotein	NULL
,	NULL
gp34	NULL
,	NULL
that	NULL
is	NULL
specifically	NULL
induced	NULL
by	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
transactivator	NULL
p40'*	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:1313-1325	NULL
.	NULL

Miyoshi	NULL
,	NULL
L	NULL
,	NULL
I.	NULL
Kubonishi	NULL
,	NULL
S.	NULL
Yoshimoto	NULL
,	NULL
and	NULL
Y.	NULL
Shiraishi	NULL
.	NULL

1981	NULL
.	NULL

A	NULL
T-cell	NULL
line	NULL
derived	NULL
from	NULL
normal	NULL
human	NULL
cord	NULL
leukocytes	NULL
by	NULL
coculturing	NULL
with	NULL
human	NULL
leukemic	NULL
T-cells	NULL
.	NULL

Jpn	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

72:978-981	NULL
.	NULL

Morimoto	NULL
,	NULL
S.	NULL
,	NULL
Y.	NULL
Kanno	NULL
,	NULL
Y.	NULL
Tanaka	NULL
,	NULL
Y.	NULL
Tokano	NULL
,	NULL
H.	NULL
Hashimoto	NULL
,	NULL
S.	NULL
Jacquot	NULL
,	NULL
C.	NULL
Morimoto	NULL
,	NULL
S.	NULL
F.	NULL
Schlossman	NULL
,	NULL
H.	NULL
Yagita	NULL
,	NULL
K.	NULL
Okumura	NULL
,	NULL
and	NULL
T.	NULL
Kobata	NULL
.	NULL

2000	NULL
.	NULL

CD134L	NULL
engagement	NULL
enhances	NULL
human	NULL
B	NULL
cell	NULL
Ig	NULL
production	NULL
:	NULL
CD154/	NULL
€D40	NULL
,	NULL
CD70/CD27	NULL
,	NULL
and	NULL
CD134/CD134L	NULL
interactions	NULL
coordinately	NULL
regulate	NULL
T	NULL
cell-dependent	NULL
B	NULL
cell	NULL
responses	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

164:4097-4104	NULL
.	NULL

Moriuchi	NULL
,	NULL
H.	NULL
,	NULL
M.	NULL
Moriuchi	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1998	NULL
.	NULL

Factors	NULL
secreted	NULL
by	NULL
human	NULL
T	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-I	NULL
)	NULL
-infected	NULL
cells	NULL
can	NULL
enhance	NULL
or	NULL
inhibit	NULL
replication	NULL
of	NULL
HIV-1	NULL
in	NULL
HTLV-1-uninfected	NULL
cells	NULL
:	NULL
implications	NULL
for	NULL
in	NULL
vivo	NULL
coinfection	NULL
with	NULL
HTLV-I	NULL
and	NULL
HIV-1	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187:1689-1697	NULL
.	NULL

Ohshima	NULL
,	NULL
Y.	NULL
,	NULL
Tanaka	NULL
,	NULL
H.	NULL
Tozawa	NULL
,	NULL
Y.	NULL
Takahashi	NULL
,	NULL
C.	NULL
Maliszewski	NULL
,	NULL
and	NULL
G.	NULL
Delespesse	NULL
.	NULL

1997	NULL
.	NULL

Expression	NULL
and	NULL
function	NULL
of	NULL
OX40	NULL
ligand	NULL
on	NULL
human	NULL
dendritic	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:3838-3848	NULL
.	NULL

Ohshima	NULL
,	NULL
Y.	NULL
,	NULL
L.-P.	NULL
Yang	NULL
,	NULL
T.	NULL
Uchiyama	NULL
,	NULL
Y.	NULL
Tanaka	NULL
,	NULL
P.	NULL
Baum	NULL
,	NULL
M.	NULL
Sergerie	NULL
,	NULL
P.	NULL
Hermann	NULL
,	NULL
and	NULL
G.	NULL
Delespesse	NULL
.	NULL

1998	NULL
.	NULL

OX40	NULL
costimulation	NULL
enhances	NULL
interleukin-4	NULL
(	NULL
IL-4	NULL
)	NULL
expression	NULL
at	NULL
priming	NULL
and	NULL
promotes	NULL
the	NULL
differentiation	NULL
of	NULL
naive	NULL
human	NULL
CD4*	NULL
T	NULL
cells	NULL
into	NULL
high	NULL
IL-4-producing	NULL
effectors	NULL
.	NULL

Blood	NULL
92:3338-3345	NULL
.	NULL

Okamoto	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Matsuyama	NULL
,	NULL
S.	NULL
Mori	NULL
,	NULL
Y.	NULL
Hamamoto	NULL
,	NULL
N.	NULL
Kobayashi	NULL
,	NULL
N.	NULL
Yamamoto	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
K.	NULL
Shimotohno	NULL
.	NULL

1989	NULL
.	NULL

Augmentation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
gene	NULL
expression	NULL
by	NULL
tah	NULL
ENHANCED	NULL
33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

HIV-1	NULL
PRODUCTION	NULL
BY	NULL
OX40	NULL
COSTIMULATION	NULL
-	NULL
6757	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retrovir	NULL
.	NULL

5:131-138	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
xB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2336-2340	NULL
.	NULL

Pankow	NULL
,	NULL
R.	NULL
,	NULL
H.	NULL
Durkop	NULL
,	NULL
U.	NULL
Latza	NULL
,	NULL
H.	NULL
Krause	NULL
,	NULL
U.	NULL
Kunzendorf	NULL
,	NULL
T.	NULL
Pohl	NULL
,	NULL
and	NULL
S.	NULL
Bulfone-Paus	NULL
.	NULL

2000	NULL
.	NULL

The	NULL
HTLV-1	NULL
Tax	NULL
protein	NULL
transcriptionally	NULL
modulates	NULL
OX40	NULL
antigen	NULL
expression	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

165:263-270	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
E.	NULL
Duh	NULL
,	NULL
W.	NULL
C.	NULL
Timmer	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
J.	NULL
S.	NULL
Justement	NULL
,	NULL
S.	NULL
Stanley	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1990	NULL
.	NULL

Interleukin	NULL
6	NULL
induces	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
expression	NULL
in	NULL
infected	NULL
monocytic	NULL
cells	NULL
alone	NULL
and	NULL
in	NULL
synergy	NULL
with	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
by	NULL
transcriptional	NULL
and	NULL
post-transcrip-tional	NULL
mechanisms	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:151-158	NULL
.	NULL

Ross	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
A.	NULL
J.	NULL
Buckler-White	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
G.	NULL
Englund	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1991	NULL
.	NULL

Contribution	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
binding	NULL
motifs	NULL
to	NULL
the	NULL
repli-cative	NULL
capacity	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
:	NULL
distinct	NULL
patterns	NULL
of	NULL
viral	NULL
growth	NULL
are	NULL
determined	NULL
by	NULL
T-cell	NULL
types	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4350-4358	NULL
.	NULL

Sousa	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
A.	NULL
F.	NULL
Chaves	NULL
,	NULL
M.	NULL
Doroana	NULL
,	NULL
F.	NULL
Antunes	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
M.	NULL
Victorino	NULL
.	NULL

1999	NULL
.	NULL

Early	NULL
reduction	NULL
of	NULL
the	NULL
over-expression	NULL
of	NULL
CD40L	NULL
,	NULL
OX40	NULL
and	NULL
Fas	NULL
on	NULL
T	NULL
cells	NULL
in	NULL
HIV-1	NULL
infection	NULL
during	NULL
triple	NULL
anti-retroviral	NULL
therapy	NULL
:	NULL
possible	NULL
implications	NULL
for	NULL
lymphocyte	NULL
traffic	NULL
and	NULL
functional	NULL
recovery	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

116:307-315	NULL
.	NULL

Suzuki	NULL
,	NULL
Y.	NULL
,	NULL
Y.	NULL
Koyanagi	NULL
,	NULL
Y.	NULL
Tanaka	NULL
,	NULL
T.	NULL
Murakami	NULL
,	NULL
N.	NULL
Misawa	NULL
,	NULL
N.	NULL
Maeda	NULL
,	NULL
T.	NULL
Kimura	NULL
,	NULL
H.	NULL
Shida	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Hoxie	NULL
,	NULL
W.	NULL
A.	NULL
O'Brien	NULL
,	NULL
and	NULL
N.	NULL
Yamamoto	NULL
.	NULL

1999	NULL
.	NULL

Determinant	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
for	NULL
efficient	NULL
replication	NULL
under	NULL
cytokine-induced	NULL
CD4*	NULL
T-helper	NULL
1	NULL
(	NULL
Th1	NULL
)	NULL
-	NULL
and	NULL
Th2-type	NULL
condi-tions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:316-324	NULL
Szabo	NULL
,	NULL
J.	NULL
,	NULL
Z.	NULL
Beck	NULL
,	NULL
E.	NULL
Csoman	NULL
,	NULL
X.	NULL
Liu	NULL
,	NULL
I	NULL
Andriko	NULL
,	NULL
J	NULL
.	NULL

Kiss	NULL
,	NULL
A.	NULL
Basci	NULL
,	NULL
P.	NULL
Ebbesen	NULL
,	NULL
and	NULL
F.	NULL
D.	NULL
Toth	NULL
.	NULL

1999	NULL
.	NULL

Differential	NULL
patterns	NULL
of	NULL
interaction	NULL
between	NULL
HIV	NULL
type	NULL
1	NULL
and	NULL
HTLV	NULL
type	NULL
1	NULL
in	NULL
monocyte-derived	NULL
macrophages	NULL
cultured	NULL
in	NULL
vitro	NULL
:	NULL
implications	NULL
for	NULL
in	NULL
vivo	NULL
coinfection	NULL
with	NULL
HIV	NULL
type	NULL
1	NULL
and	NULL
HTLV	NULL
type	NULL
1	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retrovir	NULL
.	NULL

15:1653-1666	NULL
.	NULL

Tanaka	NULL
,	NULL
Y.	NULL
,	NULL
T.	NULL
Inoi	NULL
,	NULL
H.	NULL
Tozawa	NULL
,	NULL
N.	NULL
Yamamoto	NULL
,	NULL
and	NULL
Y.	NULL
Hinuma	NULL
.	NULL

1985	NULL
.	NULL

A	NULL
glycoprotein	NULL
antigen	NULL
detected	NULL
with	NULL
new	NULL
monoclonal	NULL
antibodies	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
human	NULL
lymphocytes	NULL
infected	NULL
with	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type-1	NULL
(	NULL
HTLV-I	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
36:549-555	NULL
.	NULL

Tanaka	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Yasumoto	NULL
,	NULL
H.	NULL
Nyunoya	NULL
,	NULL
T.	NULL
Ogura	NULL
,	NULL
M.	NULL
Kikuchi	NULL
,	NULL
K.	NULL
Shimo-tohno	NULL
,	NULL
H.	NULL
Shiraki	NULL
,	NULL
N.	NULL
Kuroda	NULL
,	NULL
H.	NULL
Shida	NULL
,	NULL
and	NULL
H.	NULL
Tozawa	NULL
.	NULL

1990	NULL
.	NULL

Generation	NULL
and	NULL
characterization	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
against	NULL
multiple	NULL
epitopes	NULL
on	NULL
the	NULL
C-terminal	NULL
half	NULL
of	NULL
envelope	NULL
gp46	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type-1	NULL
(	NULL
HTLV-1	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
46:675-681	NULL
.	NULL

Tanaka	NULL
,	NULL
Y.	NULL
,	NULL
A.	NULL
Yoshida	NULL
,	NULL
H.	NULL
Tozawa	NULL
,	NULL
H.	NULL
Shida	NULL
,	NULL
H.	NULL
Nyunoya	NULL
,	NULL
and	NULL
K.	NULL
Shimo-tolhno	NULL
.	NULL

1991	NULL
.	NULL

Production	NULL
of	NULL
a	NULL
recombinant	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type-1	NULL
trans-activator	NULL
(	NULL
tax	NULL
;	NULL
)	NULL
antigen	NULL
and	NULL
its	NULL
utilization	NULL
for	NULL
generation	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
against	NULL
various	NULL
epitopes	NULL
on	NULL
the	NULL
tax	NULL
,	NULL
antigen	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
48:623-630	NULL
.	NULL

Tanaka	NULL
,	NULL
Y.	NULL
,	NULL
Y.	NULL
Koyanagi	NULL
,	NULL
R.	NULL
Tanaka	NULL
,	NULL
Y.	NULL
Kumazawa	NULL
,	NULL
T.	NULL
Nishimura	NULL
,	NULL
and	NULL
N.	NULL
Yamamoto	NULL
.	NULL

1997	NULL
.	NULL

Productive	NULL
and	NULL
lytic	NULL
infection	NULL
of	NULL
human	NULL
CD4*	NULL
type	NULL
1	NULL
helper	NULL
T	NULL
cells	NULL
with	NULL
macrophage-tropic	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
virol	NULL
.	NULL

71:465-470	NULL
.	NULL

Tozawa	NULL
,	NULL
H.	NULL
,	NULL
S.	NULL
Andob	NULL
,	NULL
Y.	NULL
Takayama	NULL
,	NULL
Y.	NULL
Tanaka	NULL
,	NULL
B.	NULL
Lee	NULL
,	NULL
H.	NULL
Nakamura	NULL
,	NULL
M.	NULL
Hayami	NULL
,	NULL
and	NULL
Y.	NULL
Hinuma	NULL
.	NULL

1988	NULL
.	NULL

Species-dependent	NULL
antigenicity	NULL
of	NULL
the	NULL
34-kDa	NULL
glycoprotein	NULL
found	NULL
on	NULL
the	NULL
membrane	NULL
of	NULL
various	NULL
primate	NULL
lymphocytes	NULL
transformed	NULL
by	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type-1	NULL
(	NULL
HTLV-1	NULL
)	NULL
and	NULL
simian	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
(	NULL
STLV-I	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
41:231-238	NULL
.	NULL

Tsunetsugu-Yokota	NULL
,	NULL
Y.	NULL
,	NULL
T.	NULL
Kato	NULL
,	NULL
S.	NULL
Yasuda	NULL
,	NULL
Z.	NULL
Matsuda	NULL
,	NULL
Y.	NULL
Suzuki	NULL
,	NULL
Y.	NULL
Koyanagi	NULL
,	NULL
N.	NULL
Yamamoto	NULL
,	NULL
K.	NULL
Akagawa	NULL
,	NULL
M.	NULL
W.	NULL
Cho	NULL
,	NULL
and	NULL
T.	NULL
Takemori	NULL
.	NULL

2000	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
during	NULL
antigen-dependent	NULL
activation	NULL
of	NULL
primary	NULL
T	NULL
cells	NULL
by	NULL
dendritic	NULL
cells	NULL
.	NULL

J.	NULL
Leukoc	NULL
.	NULL

Biol	NULL
.	NULL

67:432-440	NULL
.	NULL

Wang	NULL
,	NULL
S.	NULL
,	NULL
Y.-J	NULL
.	NULL

Kim	NULL
,	NULL
C.	NULL
Bick	NULL
,	NULL
S.	NULL
H.	NULL
Kim	NULL
,	NULL
and	NULL
B.	NULL
S.	NULL
Kwon	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
potential	NULL
roles	NULL
of	NULL
4-1BB	NULL
costimulation	NULL
in	NULL
HIV	NULL
type	NULL
1	NULL
infection	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retrovir	NULL
.	NULL

14:223-231	NULL
.	NULL

Zack	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
A.	NULL
J.	NULL
Cann	NULL
,	NULL
J.	NULL
P.	NULL
Lugo	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Chen	NULL
.	NULL

1988	NULL
.	NULL

HIV-1	NULL
production	NULL
from	NULL
infected	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
after	NULL
HTLV-1	NULL
induced	NULL
mitogenic	NULL
stimulation	NULL
.	NULL

Science	NULL
240:1026-1029	NULL
.	NULL

